Contribution of polymeric materials to progress in xenotransplantation of microencapsulated cells - A review by Mahou, Redouan et al.
For Peer Review
 
 
 
 
 
 
Contribution of polymeric materials to progress in 
xenotransplantation of microencapsulated cells - A review 
 
 
Journal: Xenotransplantation 
Manuscript ID XEN-16-R-0011.R1 
Manuscript Type: Review 
Date Submitted by the Author: n/a 
Complete List of Authors: Mahou, Redouan; University of Toronto 
Passemard, Solène; Ecole polytechnique federale de Lausanne Faculte des 
sciences de base 
Carvello, Michele; Ospedale San Raffaele 
Petrelli, Alessandra; Ospedale San Raffaele 
Noverraz, François; Ecole polytechnique federale de Lausanne Faculte des 
sciences de base 
Gerber, Sandrine; Ecole polytechnique federale de Lausanne Faculte des 
sciences de base 
Wandrey, Christine; EPFL, SV-IBI-LMRP 
Keywords: 
Cell microencapsulation, Hydrogels, Permeability, Biocompatibility, 
Xenotransplantation 
Topics: 
Cells - Islets, Cells - Other (e.g. neural), Transplantation - small animal 
models, Transplantation - large animal/preclinical models, 
Immunosuppression 
  
 
 
Xenotransplantation
Xenotransplantation
For Peer Review
1 
 
 
 
 
 
 
Contribution of polymeric materials to 
progress in xenotransplantation of 
microencapsulated cells - A review 
 
Redouan Mahou,
1,3
 Solène Passemard,
1
 Michele Carvello,
2
 Alessandra Petrelli,
2
 François 
Noverraz,
1
 Sandrine Gerber-Lemaire,
1*
 Christine Wandrey
1 
 
1
Interfaculty Institute of Bioengineering and Institute of Chemical Sciences and Engineering, 
Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland 
2
Department of Surgery, San Raffaele Scientific Institute, Milan, Italy 
3
Institute for Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada 
 
Address reprint requests to:  
Sandrine Gerber-Lemaire  
Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, 
EPFL SB ISIC, Batochime, CH-1015 Lausanne, Switzerland. Tel: +41 21 693 9372; Fax: +41 21 
693 5550; E-mail: sandrine.gerber@epfl.ch   
Page 1 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
 
 
 
 
 
Abstract: Cell microencapsulation and subsequent transplantation of the microencapsulated cells 
require multidisciplinary approaches. Physical, chemical, biological, engineering, and medical 
expertise has to be combined. Several natural and synthetic polymeric materials and different 
technologies have been reported for the preparation of hydrogels, which are suitable to protect 
cells by microencapsulation. However, owing to the frequent lack of adequate characterization of 
the hydrogels and their components as well as incomplete description of the technology, many 
results of in vitro and in vivo studies appear contradictory or cannot reliably be reproduced. This 
review addresses the state of the art in cell microencapsulation with special focus on 
microencapsulated cells intended for xenotransplantation cell therapies. The choice of materials, 
the design and fabrication of the microspheres, as well as the conditions to be met during the cell 
microencapsulation process, are summarized and discussed prior to presenting research results of 
in vitro and in vivo studies. Overall, this review will serve to sensitize medically educated 
specialists for materials and technological aspects of cell microencapsulation. 
Keywords: Cell microencapsulation, hydrogels, mechanical resistance, permeability, 
biocompatibility, xenotransplantation. 
Abbreviations: Alg-CS, alginate-cellulose sulfate; APA, alginate-poly(L-lysine)-alginate 
capsules; Ca-alg, calcium alginate; cryo-SEM, cryo-scanning electron microscopy; DDA, degree 
of deacetylation; ECM, extra-cellular matrix; FGF-1, heparin-binding growth factor 1; G, α-L-
guluronic acid; HPC, hydroxypropyl cellulose; IL, interleukin; ISEC, inverse size-exclusion 
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chromatography; LCST, lower critical solution temperature; M, D-mannuronic acid; MWCO, 
molecular weight cut-off; Na-alg, sodium alginate; NICCs, neonatal pig islet-like cell clusters; 
PEG, poly(ethylene glycol); PLL, poly(L-lysine); PLO, poly(L-ornithine); PMCG, 
poly(methylene-co-guanidine); PNIPAA, poly(N-isopropylacrylamide); PNVIBA, poly(N-
vinylisobutyramide); RGD, arginylglycylaspartic acid; TNF, tumor necrosis factor; UCST, upper 
critical solution temperature; VEGF, vascular endothelial growth factor;  
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Introduction 
Cell-based therapy is an attractive approach to treat several end-stage diseases. The Food and 
Drug Administration (FDA) defines cell-based therapy as “the prevention, treatment, cure or 
mitigation of diseases or injuries in humans by the administration of autologous, allogeneic or 
xenogeneic cells that have been manipulated or altered ex vivo" [1]. While the whole-organ 
transplantation is limited by the shortage of donors and the need of major surgery, cell-based 
therapy could overcome both obstacles. Indeed, xenotransplantation will offer an inexhaustible 
source of cells, and these cells could be delivered near the target site using non-invasive 
procedures.  
In spite of the enormous potential of such approach, progress in the field of cell-based therapy 
has been hampered for several reasons, in particular due to issues of maintaining cell viability 
and of the identification of "non-self" cells by the immune system causing transplant rejection. 
Although better patient and transplant survival rates are achievable by the administration of 
immunosuppressive treatment, major challenges such as adverse effects associated with these 
drugs and the risks of long-term immunosuppression are still to be overcome.  
The immobilization of cells within a hydrogel material has be n identified as efficient strategy to 
provide mechanical and immune protection to the cells, and to maintain their viability and 
metabolic functionality for subsequent therapeutic applications [2-3]. Successful applications 
Page 4 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
 
 
 
 
 
undoubtedly require a multidisciplinary input from materials scientists, chemists, biologists, 
engineers, and surgeons.  
The focus of the present review will be on cell microencapsulation, even though the 
immobilization and protection of cells is achievable also by other techniques such as 
immobilization in films, extravascular chambers or in hollow fibers. This review provides an 
overview of suitable materials under study for cell microencapsulation and discusses the special 
features of the technologies applied so far. The paper is mainly addressed to medically educated 
readers working on developing therapies that rely on hydrogels. The selection of suitable 
material, the design and preparation of spherical hydrogels, as well as the main requirements to 
be fulfilled during the cell immobilization process are summarized and discussed. Recent trials 
towards transplantation of xenogeneic microencapsulated cells in order to treat congenital or 
acquired hormone/enzyme deficiencies as well as degenerative/inflammatory diseases complete 
this review. 
 
Cell microencapsulation 
Microencapsulation denotes the physical entrapment of a gas, liquid, or solid within a 
surrounding material with dimensions in the micrometer range. It has gained interest in domains 
such as agriculture, food, cosmetics, construction, and analytics. Microencapsulation also 
includes the entrapment of biologically active substances such as cells, tissue, enzymes, bacteria, 
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or DNA. For such applications, the term bioencapsulation is frequently used. An ambitious 
challenge in bioencapsulation is cell microencapsulation, which denotes the entrapment of cells 
while maintaining their viability and metabolic functionality (Figure 1). 
Cell immobilization in polymer-based hydrogels was first proposed in 1933 by Bisceglie [4], who 
demonstrated that insulin-producing cells remained viable and metabolically active after 
immobilization. Three decades later, Chang proposed the use of semi-permeable membranes as 
immune-isolating devices, and introduced the term “artificial cells” to define the concept of cell 
microencapsulation [5]. As shown in Fig. 1, cell microencapsulation offers protection against 
mechanical stress or deteriorating environmental effects. The surrounding hydrogel allows for 
bidirectional diffusion of molecules essential for cell metabolism such as oxygen and nutrients, 
and the release of metabolic products. Simultaneously, the passage of immune cells and 
antibodies is restricted, giving rise to an immunoprotection for the encapsulated cells. Therapies 
relying on microencapsulated cells could therefore result in the reduction or even avoidance of 
the administration of immunosuppressive drugs on the one hand, and on the other hand permit the 
transplantation of nonhuman cells, which is a promising alternative considering the limited 
availability of donor organs [6-7]. The therapeutic potential of the transplantation of 
microencapsulated cells has been reported for the treatment of a variety of diseases, including 
liver failure [8-10], renal failure [11-13], cancer [14], and diabetes mellitus [15-18]. 
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Hydrogels for cell microencapsulation 
Since the pioneering work of Wichterle on cross-linked poly(hydroxyethyl methacrylate) [19], 
hydrogels have been of great interest to biomaterial scientists [20-24]. Hydrogels consist of a 
three-dimensional network of natural [25] or synthetic [26] polymer chains. Due to their high 
water content, hydrogels have been recognized to meet the requirements for bioencapsulation 
[27-30]. The cross-linking mechanism determines their classification as physical or chemical 
hydrogels. Hydrogels are called “physical” or “reversible” if the networks are held together by 
physical forces only. Chemical hydrogels, also referred to as “permanent”, are obtained when 
polymers having reactive groups link together via covalent bonds. Hydrogels used for cell 
microencapsulation are hereinafter designated as microspheres, which is a generic name that 
refers to the size and shape of the materials. According to other classifications of microspheres, 
which take into account the physical structure of the hydrogel, microspheres are called 
microbeads if the hydrogel is radially homogeneous. Contrary, the term microcapsule is used if 
the microsphere is radially heterogeneous, for example, if a microbead was additionally coated 
with other polymers or if hydrogel surrounds a liquid core. 
 
Physical hydrogels 
Physically cross-linked hydrogels possess physical junction domains associated with chain 
entanglements, ionic or hydrogen bonding, and hydrophobic interactions [31-36]. The interest in 
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these physical hydrogels is obvious since they are easily obtainable in a one-step process while 
avoiding the use of cross-linking agents. Only physical hydrogels obtained via ionic bonding or 
induced by temperature change are discussed herein. 
 
Physical hydrogels by ionic bonding. The principle of preparing physical hydrogels via ionic 
bonding is schematically represented in Fig. 2. First, when a polyelectrolyte (polymer bearing 
many positive or negative charges) interacts with multivalent ions of the opposite charge, it may 
form a physical hydrogel known as “ionotropic” hydrogel. Second, when polyelectrolytes of 
opposite charges are mixed, they may gel depending on their polymer backbone constitution, 
concentrations, the ionic strength, as well as the pH of the solution. The products of such 
polyanion/polycation interactions are known as complex coacervates, polyelectrolyte complexes, 
or simplexes. A polyanion was selected in Fig. 2 as example to demonstrate the principle. The 
complexation of polycations is achievable similarly. 
 
A description of polymers that have been explored in terms of their ability to form physical 
hydrogels via ionic bonding is presented below. 
Sodium alginate. The designation sodium alginate (Na-alg) does not refer to a unique polymer 
structure but to a variety of polymers, which are composed of the same two monomeric units, β-
D-mannuronic acid (M) and α-L-guluronic acid (G), but arranged in different linear sequences 
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[37, 38]. As shown in Fig. 3, the monomeric units can be arranged as blocks of different lengths 
or randomly alternated in the polymer chains. Due to the advantageous gelling properties in 
contact with divalent cations, the Na-alg family is the most frequently used polymeric material 
for cell microencapsulation. However, the properties of alg-based hydrogels are very sensitive to 
the nature of the Na-alg and the preparation conditions. Consequently, the knowledge of the 
molecular and macromolecular characteristics of Na-alg is crucial for the production of defined 
hydrogels. Fig. 4 summarizes characteristics of Na-alg that influence the properties of alg-based 
hydrogels. 
The chemical composition of Na-alg has an impact on the stability and permeability of the alg-
based hydrogels [38-40], attributed to ionic bonding between G units and divalent cations, 
referred to as the egg-box model [41]. The importance of the G units is highlighted by the fact 
that the strength of alg-based hydrogels is di ectly related to the total content of G units and the 
average length of the G blocks in Na-alg [42]. Furthermore, it has been demonstrated that 
calcium alginate beads (Ca-alg) prepared from Na-alg with high G content are more permeable 
and exhibit less water uptake compared to Ca-alg prepared from Na-alg with high M content 
[43]. The composition-biocompatibility relationship, however, is still a matter of controversy. 
Some studies reported that Na-alg with a high content of M evoke an inflammatory response by 
stimulating monocytes to produce cytokines such as interleukin IL-1, IL-6 and TNF [44]. 
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Moreover, antibodies were found when high-M alg-based hydrogels were transplanted, but not in 
the case of high-G alg materials [45]. In contrast, other studies claim high-G alg-based hydrogels 
to be associated with more severe cell overgrowth [46]. In addition to the composition, the purity 
of the Na-alg cannot be neglected [47]. There is a consensus that in vitro and in vivo studies have 
to be conducted using highly purified Na-alg, free of endotoxin, proteins, and polyphenols. 
The molar mass of the Na-alg and the concentration of its solution are further important 
parameters. Na-alg is available with molar mass in the range of 50 to 3000 kg/mol [48, 49]. The 
viscosity of a Na-alg solution increases with both the molar mass and the concentration of Na-
alg. Therefore, a compromise between the molar mass of Na-alg and its concentration is needed 
to adapt the viscosity of the solution to a specific application in terms of cell type and technology. 
A selection of applications of Na-alg-based physical hydrogels is listed in Table 1. 
In spite of favorable properties, alg-based physical hydrogels suffer from drawbacks such as 
limited mechanical stability, insufficient durability, and too high permeability. They are dissolved 
when chelators such as phosphate, lactate, citrate and non-gelling cations are present above a 
certain concentration [62]. To overcome such problems, subsequent coating of the initially 
formed hydrogels with polycations to form a polyanion-polycation complex has been proposed. 
Poly(L-lysine) (PLL), poly(L-ornithine) (PLO), and chitosan are the main polycations that have 
been suggested for the coating of alg-based hydrogels. A final layer of Na-alg is needed to 
neutralize the excess of positive charges, to turn the surface charge into negative, and thus to 
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avoid biocompatibility problems caused primarily by attachment of proteins to a surface with 
positive charges. 
 
Poly(L-lysine) and poly(L-ornithine). Since the first transplantation of islets of Langerhans 
microencapsulated in alg-based hydrogel coated with PLL was published [63], the application of 
PLL as coating material for alg-based hydrogels has been widely reported. Typically, the 
alginate-poly(L-lysine)-alginate (APA) microcapsule comprises three main components: a core of 
Ca-alg surrounded by an alginate-PLL complex and an outer coating of Na-alg. The coating 
reinforces the mechanical resistance of Ca-alg and allows for controlling the permeability. The 
surrounding polyanion-polycation complex reduces the osmotic swelling and thus stabilizes the 
microcapsule size. Numerous studies using APA to encapsulate cells have been reported [64-70]. 
Despite improvement of the physical properties of alg hydrogels upon coating with PLL, the 
immunological response upon transplantation of APA remains a major challenge. A multitude of 
studies have demonstrated that Ca-alg is better tolerated in vivo than polycation-coated 
microcapsules [71-73]. The proposed mechanism involves the adhesion of proteins to the surface 
of the hydrogel when this latter is exposed to blood, plasma or peritoneal fluid. This adhesion 
initiates the reactive protein cascades and serves as cellular anchor [74-78]. To overcome these 
biocompatibility issues, different methods have been proposed to reduce the protein adsorption to 
the surface of APA. For instance, grafting biocompatible poly(ethylene glycol) (PEG) pendent 
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chains [79-81],  optimizing the APA composition [82] and size [83], or using epimerized Na-alg 
[84] were reported. 
Other efforts were directed towards exploring the suitability of other polycations as coating 
materials. It has been suggested that using PLO has advantages compared to the use of PLL [85-
87]. PLO is more hydrophilic than PLL due to the difference in the chemical structure, as shown 
in Fig. 5. PLO binds more efficiently to the surface of Ca-alg, which in turn has a positive impact 
on the physical properties of the microspheres. Microspheres coated with PLO exhibited higher 
hydrophilicity, improved mechanical properties, and superior resistance to swelling and damage 
under osmotic stress [88, 89]. In terms of biocompatibility, however, the suitability of using PLO 
instead of PLL is still controversial. Likewise PLL, the immunological response to PLO 
containing microcapsules was reduced by PEGylation of the outer layer [90]. While some studies 
claim that promising results are obtained when replacing PLL by PLO [91-93], others suggest 
that PLL remains the best option [94, 95].  
 
Chitosan. Chitosan is a linear polysaccharide consisting of randomly distributed β(1→4) linked 
D-glucosamine and N-acetyl-D-glucosamine units, as illustrated in Fig. 6. The cationic properties 
of chitosan depend on the degree of deacetylation (DDA), which is the fraction of glucosamine 
units. The molar mass depends on the source and isolation procedure, and it can reach values up 
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to 500 kg/mol. Lower molar masses and oligomers are obtained by chain degradation [96]. 
Chitosan is a non-permanently charged cationic polyelectrolyte. Its charge density and solubility 
strongly depend on the DDA and pH. With a pKa value of approximately 6.5, chitosan is 
positively charged and soluble in acidic to neutral media, only if the DDA exceeds 60%. 
Exceptions are oligomers. 
Similarly to PLL and PLO, chitosan has been applied to coat Ca-alg or Ba-alg [97]. However, 
microspheres with a Ca-alg core covered by an alginate-chitosan complex membrane can also be 
made in a one-stage process by dropping Na-alg into an aqueous solution containing chitosan and 
calcium ions [98]. The opposite process, dropping chitosan and Ca
2+ 
solutions into Na-alg yields 
microspheres with a chitosan core and a chitosan-alginate membrane [99]. The stability, 
permeability, and biocompatibility of alg-chitosan microcapsules were intensely studied [100-
106]. Several cell types were successfully encapsulated in alg-chitosan microspheres including 
islets of Langerhans [107, 108], hepatocytes [109-114], and mesenchymal stem cells [115, 116]. 
 
Sodium cellulose sulfate and poly(methylene-co-guanidine). Alginate-cellulose sulfate-
poly(methylene-co-guanidine) microcapsules (alg-CS/PMCG) are prepared by a two steps 
process. First, a polyanion blend of Na-alg and CS is gelled in the presence of calcium ions. 
Second, a membrane is formed via the addition of PMCG. It was demonstrated that both 
mechanical resistance and permeability of alg-CS/PMCG are tunable by changing the ratio of Na-
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alg/CS in the polyanion blend and the chemical composition [117-119]. A subsequent coating 
with lower molar mass Na-alg allowed adjusting the permeability over a wide range, suitable for 
cell microencapsulation and immunoprotection, without compromising the durability of the 
microspheres. A number of studies using alg-CS/PMCG microcapsules were published [120-
125]. However, the in vivo biocompatibility remains a major issue. Indeed, when a human whole 
blood model was used to assess the inflammatory properties of alg-CS/PMCG microspheres, they 
have triggered complement and leukocyte activation over time, although they were still less 
activating than PLL-containing microcapsules [71]. 
 
Physical hydrogel by temperature-response. The preparation of temperature-responding 
hydrogels is emerging as a promising tool for various biomedical applications [126], including 
cell microencapsulation. Such hydrogels are obtained from polymers that respond to temperature 
change and undergo a sol-gel transition [127, 128]. Derivatives of methylcellulose [129], 
chitosan [130], hydroxypropyl cellulose (HPC) [131], poly(N-vinylisobutyramide) (PNVIBA) 
[132], and poly(N-isopropylacrylamide) (PNIPAAm) [133-136] have been reported to exhibit 
gelation upon temperature change. The latter is a very attractive temperature-responsive polymer 
since it exhibits a sharp sol-gel transition in water at 34.3°C. Thus injecting a polymer solution 
prepared at room temperature (rt) can lead in situ to the formation of hydrogels at 37°C. 
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Moreover, the formation of hydrogels from PNIPAAm is tunable by changing the preparation 
conditions [137-139]. 
 
Chemical hydrogels 
Chemical hydrogels are mostly applied in cell microencapsulation when high mechanical 
resistance and long-term durability are required. For this purpose, several combinations of 
polymers and preparation conditions have been tested in regards to their suitability to encapsulate 
cells within chemical hydrogels. However, only a limited number of combinations have been 
identified for this purpose. Table 2 lists some examples that have been used to immobilize cells. 
Numerous criteria must be considered when designing a chemical hydrogel for cell 
microencapsulation. The process of hydrogel formation must not negatively influence cell 
integrity and viability and should not involve harsh conditions, toxic solvents and reactants [158]. 
Because cells are suspended in a liquid precursor solution prior to the encapsulation process, the 
choice of precursors is limited to water-soluble components. The aqueous solution must be 
buffered with appropriate osmolality to prevent cell lysis. The rheological properties of the 
precursor solution are crucial to maintain cell viability and cell-cell adhesion during the 
encapsulation process. Mixing cells with highly viscous solutions can lead to a significant 
decrease in cell viability [159]. 
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Hybrid hydrogels 
Novel hydrogel types that combine physical and chemical cross-linking, are being emerging as 
adequate candidates for cell microencapsulation. The physical interactions allow for fast gelation 
and spherical shape formation, while biocompatible covalent cross-linking ensures the 
reinforcement of the hydrogel networks, along with tunable permeability and gel stiffness. 
For the preparation of APA microspheres with covalent cross-linking between adjacent layers, 
PLL was equipped with phenyl azide residues that create covalent bonds with Ca-alg when 
irradiated with UVA [160]. The photo-initiated cross-linking was shown to be cell compatible, 
and yielded stable microspheres up to 3 years in alkaline buffer (pH 12), whereas standard APA 
disappeared within 1 min. Another strategy reported the replacement of the final alginate layer of 
APA capsules by poly(methyl vinyl ether-alt-maleic anhydride) (PMM) and poly(vinyl dimethyl 
azlactone-co-methacrylic acid) (PMV) to form stable covalent amide bonds with PLL, 
neutralizing the polycation layer [161]. 
Further, the involvement of methacrylate polymers into physical microspheres, and subsequent 
covalent cross-linking was reported [162, 163]. It was demonstrated that either cross-linked shells 
or cross-linked cores are obtainable by adjusting the molar mass of the cross-linker. Approaches 
based on chemical cross-linking through complementary reactive groups attached to two 
oppositely charged polyelectrolytes were also investigated [164, 165]. Similarly, microbeads 
were prepared by ionotropic gelation of a combination of Ca-alg and sericin as inner core 
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followed by coating with chitosan and further cross-linking with genipin [166, 167]. This 
combination effectively reduced swelling and physical disintegration of the microspheres induced 
by non-gelling ions and calcium chelating agents. Higher resistance to mechanical shear force 
and improved durability against enzymatic degradation were achieved. The entrapment of vinyl 
sulfone terminated PEG in Ca-alg and subsequent Michael-type cross-linking has been reported. 
The mechanical properties of such hybrid microspheres were adjustable and suitable for cell 
microencapsulation [168-170]. 
Rather than using hydr gels obtained from oppositely charged polyelectrolytes bearing 
complementary reactive groups for chemical cross-linking, one-component hybrid hydrogels are 
also being developed and tested for cell microencapsulation. A one-component system denotes 
hybrid hydrogels prepared from polymers able to form simultaneously both physical and 
chemical links. Such polymers are very often a modified macromolecule or biopolymer. For 
instance, the preparation of hybrid alg-based microspheres was achieved by equipping Na-alg 
with azide-terminated PEG pendent chains [171]. The azide end group forms chemical cross-
links via the Staudinger reaction by incubation in a gelation bath containing phosphine-
functionalized agents. Human pancreatic islets were encapsulated using such systems [172-174]. 
Similarly, Na-alg with thiol end groups was prepared [175, 176]. The modified Na-alg 
maintained the gelling capacity in the presence of calcium ions, while the thiol end groups 
ensured the preparation of a chemically cross-linked network via disulfide bond formation. Being 
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biocompatible, spontaneous, and catalyst free, the formation of disulfide bonds yielded hybrid 
microspheres in a one-step extrusion process under physiological temperature, pH, and 
osmolality. Good survival rate and improved proliferation were obtained upon 
microencapsulation of liver-derived cells within hybrid microspheres [177]. 
Nonetheless, the strategies described above mainly focused on the robustness of the biomaterials 
but other parameters must also be underlined. The lifetime and biocompatibility of encapsulated 
cells should be enhanced to overcome the problem of graft failure [178]. Actually, the survival of 
engrafted cells depends on the cells adhesion to the hydrogel matrix, on the vascularization 
improving the delivery of nutrients, oxygen and metabolites but also on the immune response of 
the host body. For this purpose, hybrid hydrogels containing peptides or proteins were developed. 
Mimicking the ECM, and the covalent incorporation of adhesives ligands such as galactose 
[179], RGD [180], and other types of laminin-derived recognition sequences and collagen type I 
sequence [181] have been reported. Besides these molecules, proteins such as fibrin [182] and 
collagen [183] but also glycoproteins [184] were also encapsulated to enhance cell viability. 
Moreover, the co-encapsulation of vascularization promoting factors such as VEGF [185] and 
FGF-1 [186] promoted the neovascularization by improving the viability of engrafted 
encapsulated islets. Last but not least, co-encapsulation of anti-inflammatory agents such as 
complement receptor 1 sCR1 [187], the chemokine CXCL12 [188] or the drug dexamethasone 
[189] reduced the inflammatory response and thus prolonged the graft survival. Also, anti-
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cytokine agents [190, 191] were covalently attached on the hydrogel matrix sequestrating the pro-
inflammatory cytokines highly expressed in wounded environment. 
 
 
Properties of hydrogel microspheres and their assessment 
In addition to the size and size stability as well as chemical stability, the most important 
characteristics of microspheres, which determine the applicability for subsequent transplantation, 
are their mechanical resistance, permeability, and biocompatibility. The selection of suitable 
methods to assess these parameters is not always a straightforward decision.  
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Mechanical resistance. The mechanical resistance of hydrogel microspheres is not an absolute 
parameter. It can be evaluated by several methods, each of them providing different information. 
One method to assess the mechanical resistance is the osmotic pressure test. The microspheres 
are simply exposed to water [192]. The sudden influx of water causes the microspheres to swell 
and break. A method to study the resistance to mechanical stress is the microsphere shearing test. 
A suspension of microspheres is subjected to a controlled fluid shear [193]. The number of 
broken microspheres as a function of the applied mechanical stress gives an indication of their 
mechanical resistance. Such essays have the advantage of being very simple. However, they have 
limitations: 
1) only qualitative information, restricted quantification; 2) the osmotic pressure test is reliably 
applicable only to physical hydrogels. 
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Contrary, the evaluation of the resistance and deformability of the microspheres under 
compression is considered a quantitative method [194]. A mobile probe compresses the 
microspheres at a defined speed. Microspheres having the same size can be characterized and 
compared by measuring the force corresponding to the rupture of the microsphere, and by 
comparing the mechanical resistance at a given degree of compression [195, 196]. Dependent on 
the equipment sensitivity and the hydrogel stiffness, two methods are commonly used:  
- Each microsphere is individually compressed. The mechanical resistance of 20 to 30 
microspheres needs to be analyzed to obtain statistically meaningful data. 
- A layer of microspheres is compressed. This method is suitable for capsules that burst at low 
force. A narrow size distribution is the prerequisite.  
Although several methods have been proposed to study the mechanical properties of hydrogels, 
only few have focused on measuring the mechanical properties of cell-embedding hydrogels. 
Ahearne et al. reported a non-destructive, online and real-time method that allows measuring the 
mechanical properties of hydrogels with incorporated cells [197]. 
 
Permeability. The ability to deliver metabolic products and th rapeutic proteins, but to block the 
diffusion of immune cells and antibodies, is the basis of the use of cell microencapsulation in 
biomedical applications. A defined and controllable permeability is therefore an essential 
prerequisite of hydrogel microspheres intended for transplantation.  
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The permeability of microspheres can be described by the mass transfer or diffusion coefficient 
[198, 199]. It defines the rate of diffusion of a given solute into the hydrogel microsphere. 
Another quantification is the minimum size of a solute, which is completely excluded from the 
hydrogel pores. This is usually referred to as the exclusion limit or molecular weight cut-off 
(MWCO). The determination of solute permeation can be either by diffusion into the 
microspheres (ingress) or from the microspheres (egress). 
Several experimental techniques to assess the permeability of microspheres have been described 
relying on different solute types and monitoring methods for quantifying the chosen solute. These 
include, for example, dextrans and pullulans as solutes and spectroscopy (fluorescence, UV/vis), 
measurement of radioactivity, size exclusion chromatography with concentration-sensitive 
detectors, and protein assay kits as monitoring methods [200, 201].  
An efficient technique that is being used for measuring the permeability is the inverse size-
exclusion chromatography (ISEC) [202, 203]. It has the advantage that the MWCO and its 
distribution can be determined simultaneously. The drawback is that a minimum of 10 mL of 
microspheres is so far needed for each measurement. The optimization of this method to reduce 
the volume of hydrogel microspheres would be a great achievement. 
The hydrogel mesh size, which is the space available between the macromolecular chains, has 
been also used to describe the permeability of hydrogel microspheres. Direct determination of the 
mesh size is achieved by cryo-scanning electron microscopy (cryo-SEM), a technique that images 
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the internal structure of hydrogel microspheres on a nanometer scale [204]. However, the 
manipulation of the hydrogel during freezing is critical. 
 
Biocompatibility. The assessment of the biocompatibility of hydrogel microspheres is a complex 
task due to the multitude of interactions between host body and foreign material and because 
biocompatibility is not simply a property of a material but a property of a biomaterial-host system 
[205]. Biocompatibility issues of microspheres are often connected with their ability to perform 
with an “appropriate host response” in a “specific application” [206]. A biocompatible hydrogel 
is considered to be a system that elicits no or not more than a minimal foreign body reaction. The 
success of cell microencapsulation intended for transplantation strongly depends on minimizing 
this immune response. Upon implantation of microencapsulated cells, the immune response is 
activated by the adsorption of proteins onto the microspheres surface, which will subsequently 
stimulate the recruitment of immune cells [207], and the rejection of the transplant through one of 
the many well-documented pathways [208, 209]. The immune response also elicits fibrosis 
around the hydrogels, which subsequently starves the encapsulated cells by limiting the diffusion 
of nutrients, and limits the efflux of bioactive molecules secret d from the cells [210]. Thus, most 
approaches developed to minimize the immune response to hydrogels are focused on preventing 
protein adsorption and cellular adhesion to the surface of hydrogels through the encapsulation of 
cells into biologically inert hydrogels, or modification of the hydrogel surface with biocompatible 
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materials. Very recently, beads size and shape have shown to influence the immune response of 
the foreign body [211]. It was demonstrated that larger beads (1.5 mm) reduced immune 
reactions and fibrosis in comparison to smaller beads (0.5 mm) when using different materials, 
including alginate in rats and non-human primate models [212].  
In addition to the host reaction, the cell compatibility of the hydrogel is a general 
biocompatibility prerequisite for a successful therapy using microencapsulated cells. Different 
cell types could require different hydrogel properties in terms of stiffness or hydrophobicity. In 
this context, also a minimum of microsphere volume was reported as being advantageous to 
ensure sufficient oxygen supply and to avoid necrosis [92]. This is in contradiction with results 
reported in [212]. 
 
Cell microencapsulation techniques 
Extrusion techniques 
Numerous techniques have been developed for the production of hydrogel microspheres [213, 
214]. Most of them are based on forcing the passage of the cell-containing solution through a 
needle or a nozzle, and its extrusion into a gelation bath. The simplest method comprises dripping 
with only gravitational force as the driving force. This mode is restricted to low-viscous solutions 
and yields hydrogel microspheres with diameters in the range of 1.5 to 3 mm. However, the 
challenge in cell microencapsulation is to produce preferably microspheres with diameters in the 
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range of 100 to 400 µm. Indeed, hydrogel microspheres with such dimensions have the advantage 
of a higher surface-to-volume ratio, exhibiting good transport of nutrients [215]. Subsequently, 
different processes of droplet formation, which is the first step of cell microencapsulation, are 
discussed and schematically shown in Fig. 8. A comprehensive database of different 
encapsulation technologies is available on http://www.genialab.de/WG3/. 
 
Droplet formation by coaxial air-flow. The principle of the coaxial air-flow droplet generator 
[216] is the use of air-flow to separate droplets from a needle or nozzle tip before they fall due to 
gravity into a gelling bath. Surface tension gives the droplets their near-spherical shape. 
Microspheres in the range of 200-1000 µm with good uniformity are obtained. However, the size 
distribution significantly increases for diameters below 400 µm [217]. Reasonable production 
rates are attainable by optimization [218].  
Jet breakage by a vibrating nozzle. Small (<1000 µm) and uniform (< 3 % size deviation) 
microspheres can be obtained by employing the jet-break vibrating technique [219]. The 
technology principle is that a laminar liquid jet breaks up into equally sized droplets by 
superimposed vibration of the nozzle. However, given that the droplet diameter obtained by this 
technique is 2 to 3 times larger than the nozzle diameter, the production of capsules with 
diameters < 400 µm needs extrusion nozzles of 150 µm. Therefore, this technique is not optimal 
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for the microencapsulation of large cells or cell clusters. The high mechanical stress to which the 
cells are exposed might compromise their viability.  
Droplet formation by an electrostatic potential. To obtain small uniform droplets, a high 
electrostatic potential between the needle and the receiving bath can be used [220, 221]. The 
diameter of the droplets can be tailored by controlling the electrostatic pulses [222-224].  
Jet breakage by rotating elements. This technology is especially suitable for the production of 
large batches of microspheres. Droplets are formed by rotating nozzles, a rotating disk or a 
cutting wire [225]. 
 
Emulsion techniques 
Emulsion techniques allow the formation of microspheres with relatively small diameters. The 
aqueous phase (cell-containing solution) is mixed and dispersed in an organic phase. When the 
dispersion reaches equilibrium, gel formation is initiated by cooling or by the addition of a 
gelling agent. Although the emulsion process is advantageous for large-scale production [222-
226], its use for cell microencapsulation is limited due to the broad size distribution generally 
obtained. Further, the use of an organic phase and the significant shear stress during emulsion 
may compromise cell survival [227]. 
 
Microfluidic-based cell encapsulation 
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The recent advances in microfluidics and microlithography provided effective tools to control the 
formation of hydrogel microspheres with desirable shape, size, and size distribution [228-231]. 
Microfluidics allow for the preparation of hydrogels with defined morphology such as Janus 
particles, multi-compartment microspheres and non-spherical microgels [232-239]. Droplets are 
produced when mixing an aqueous precursor solution with an oil phase such as mineral oil, 
silicone oil, corn oil, hexadecane or fluorinated oil [240]. The droplets are further internally 
crosslinked by ionic gelation or by photo-polymerization to obtain cells entrapped in hydrogel 
microspheres [241]. Obviously, the immiscibility of the two phases is a prerequisite to ensure the 
formation of spherical droplets [242, 243]. However, the viscosity of the oil has been identified 
as an important factor controlling the formation of the droplets. The results have shown that 
highly viscous liquids are emulsified into larger droplets with lower polydispersity [244]. As a 
proof of concept, several cell types have been encapsulated within hydrogel microspheres using 
microfluidic droplet formation devices [245-251]. Moreover this technology exhibits ideal 
solution for single cell encapsulation [252, 253]. The production of a sufficient numbers of 
droplets in a short-time period remains a major drawback to be overcome. There is therefore a 
need for scale up studies to adapt this technology for cell microencapsulation [254]. 
 
Conformal polymer coating 
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If the average diameter of a cell aggregate is considered as 150 µm, the total volume of a 450 µm 
diameter microcapsule is 27 times larger. This “dead” volume is an often-overlooked issue that 
can be related to a delayed metabolic response and a slowed diffusion of oxygen and nutrients 
causing cell necrosis, especially at the center of the microsphere. This issue may also represent a 
limiting factor if the transplantation of microencapsulated cells is aimed, as only limited space is 
available at the transplant site. To reduce the microsphere size, depositing a polymer coating 
directly on the surface of a cell was proposed [255]. As shown in Fig. 9, the total volume equals 
the size of the cell aggregate plus the thickness of the coating. The advantages from a mass 
transfer perspective are achieved because of the high ratio of surface to volume. The direct 
deposit of polymer coatings on the surface of cells has been achieved following different 
processes such as emulsification [212], discontinuous gradient density centrifugation [256], 
selective withdrawal [257], or interfacial polymerization [258]. Because of the relatively large 
cell or cell cluster diameter, conformal polymer coating was preferably applied to islets of 
Langerhans, using alginate [259], agarose [260], and PEG [261-263] and different chemical 
strategies were explored to modify covalently the surface of the cells [264]. Polymers such as 
PLL have been applied for conformal coating after conjugation with biocompatible molecules to 
attenuate their toxicity [265-267]. 
 
Cell microencapsulation for xenotransplantation 
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Sites of transplantation 
Different surgical sites have been so far used for the transplantation of encapsulated cells [268, 
269]. Choosing the surgical site is critical to provide capsules proper intimacy with the outside 
environment and graft vascularization. In addition to biological functionality, the ideal site for 
transplantation should be easily accessible for both placement and microcapsule retrieval. 
To accomplish these needs, several studies have investigated the peritoneal site. Indeed, the 
peritoneum is currently considered by several authors a feasible and effective site to implant both 
encapsulated islets and hepatocytes [270-275]. However, it was also shown that the peritoneal 
cavity has less chance to provide sufficient oxygen to microencapsulated cells compared to the 
kidney capsule and muscle [270]. Nonetheless, the peritoneum has shown good results, when 
used as implantation site for encapsulated cells, despite impaired insulin secretion to glucose 
stimuli and progressive loss of function in islet transplantation has been reported. Furthermore it 
has been shown that the capsules are likely to float into the peritoneal cavity with lack of 
engraftment, clot formation and subsequent poor nutrition. On the other hand, the peritoneum 
allows the transplantation of large quantity of tissue and further infusions in case of loss of graft 
function with respect to other sites [276]. In addition, the biocompatibility can be significantly 
improved by using barium-alginate microcapsules [277]. To overcome low oxygen tension, some 
authors proposed the construction of an omental pouch providing a more efficient blood supply 
by capillary neoangiogenesis [278, 279]. Indeed, it was shown that encapsulated islets, 
Page 29 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
30 
 
 
 
 
 
 
transplanted into the omental pouch, are able to restore euglycemia in NOD mice without 
immunocytes infiltration around the capsules [279, 280].  
The portal vein is traditionally used for human islet transplantation and it is now considered the 
standard site to make islets exert their function. Moreover closer contact to the vessels should 
provide efficient nutrition and blood supply. On the other hand the risk of portal vein occlusion 
and the difficult retrieval of the capsules (harboring both islets and hepatocytes) are important 
issues to be solved to optimize this site of implantation [281]. Nevertheless, portal puncture 
during acute liver failure f r HT should be balanced as a highly hazardous maneuver due both to 
coagulopathy and the enhanced risk of occlusion in pathologic liver parenchyma.  
Skin and subcutaneous tissue represent the most accessible site for microsphere transplantation 
regarding surgical implantation and retrieval [282]. Lack of blood supply could be improved by 
prevascularization of the site [283]. However, para-physiological conditions for the cells to work 
properly is difficult to obtain in these sites, thus the skin should be used for host-biocompatibility 
and immunoprotection tests. Vascularization could be improved by using the intramuscular site 
to maintain good surgical accessibility and graft monitoring. 
The kidney capsule has been widely used for murine islet transplantation [284, 285]. It provides 
good surgical accessibility and retrievability. However, the volume of encapsulated cells required 
to achieve insulin independence makes this site unconvincing for clinical translation. 
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Sources of cells for xenotransplantation 
The use of porcine cells for xenotransplantation has been intensively studied, in particular for 
islet transplantation [286, 287]. Shin et al. demonstrated that adult porcine islets from pathogen-
free miniature pigs transplanted into immunosuppressed diabetic monkeys induced fast glucose 
levels normalization. In addition, normoglycemia was maintained for more than six months in 
four cases, with no serious advert effects resulting from the transplantation [288]. Several reports 
highlighted the advantages to use neonatal pig islet-like cell clusters (NICCs) instead of adult pig 
cells. In particular, NICCs are easily digested and purified, show low level of T-cell response and 
high resistance to ischemia and inflammation [289]. Optimal functionality was observed after 12 
days of culture [290] and tolerance to xenotransplantation of NICCs can be improved by 
treatment with expanded regulatory T cells or molecules targeting innate immunity [291]. The 
ideal age at which these cell clusters should be isolated from porcine donors was established to be 
during the first month of life, with slight advantages for pigs within the first week of life [292]. 
Pig-to-monkey islet xenotransplantation was also attempted from adult genetically engineered 
pigs to overcome the metabolic and immunological barriers between species. However, the multi-
transgenic islet grafts did not show consistent long-term functionality for several months [293]. 
The use of pig cells was also investigated in the context of xenotransplantation for the treatment 
of acute liver-failure [294]. Alginate encapsulated re-aggregated neonatal pig liver cells 
demonstrated promising efficacy for the treatment of mice with acute liver failure. In addition, 
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coating of the capsules with chitosan resulted in a reduction of the attachment of macrophages 
[295]. Recently, No et al reported on the development of a method for the tri-culture of three 
types of cells from rats to produce uniformly sized and shaped micro liver tissues. Encapsulated 
in collagen-alginate composites, these cells induced a long-term survival rate of 80% in mice 
with 90% hepatectomy [296]. Other sources of transgenic cells have been investigated. In 
particular, wide-type and transgenic tilapia donors were considered for the harvesting of islet 
cells [297, 298]. Transplantation of alginate encapsulated tilapia islets into diabetic mice resulted 
in long-term (up to 210 days) metabolic control but required immunosuppressive treatment [299]. 
The significant difference between tilapia insulin and human insulin is nevertheless a strong 
limitation to clinical application of tilapia islets in cell therapy protocols. 
 
Translation of cell microencapsulation into a xenotransplantation cell therapy 
Since the first reports, in the 1980s, of hydrogel encapsulation of islet-β-cells for the treatment of 
type I diabetes mellitus, many studies on animal models addressed the different parameters which 
can improve biocompatibility, stability and functionality of encapsulated cells. Table 4 lists some 
of the animal experiments and pre-clinical studies that evaluated the xenotransplantation of 
encapsulated islets and hepatocytes. 
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The encapsulation of different islet types in Ca- and Ba-alg materials allowed restoring 
normoglycemia in xenogenic settings, without immunosuppression. Similarly, encapsulated 
xenogenic hepatocytes were able to revert acute liver failure in rodent models, in absence of 
immunosuppressive treatment. Despite these encouraging results, the demonstration of effective 
protocols in patient protocols is still very scarce. In 2011, Calafiore et al reported a phase I 
clinical trial testing alginate encapsulated islets, transplanted into the portal vein, in 4 type I 
diabetic patients obtaining transient insulin independence only in one of them, but showing 
safety, feasibility and biocompatibility of alginate capsules in humans [304]. More recently, 
Matsumoto et al published the results from a phase I/IIa xenotransplantation study of APA 
encapsulated neonatal porcine islets in 14 patients with unstable type 1 diabetes [305]. Without 
immunosuppressive treatment, the transplantation was safe and resulted in the reduction of 
unaware hypoglycemia events, but did not result in insulin independence.  
 
Concluding remarks, future directions and open questions  
The Holy Grail for transplant investigators is to avoid the use of immunosuppression. 
Encapsulation of cells and cell clusters could finally lead to this goal by setting up the conditions 
for long-term function cell therapy without the adverse effect of immunosuppressive agents. 
Nonetheless, adequate protection of cells from the immune system could expand the field of 
xenogeneic transplantation. However, despite the recent breakthrough-findings, crucial issues 
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still remain unsolved. Purity and stability of encapsulation materials should be improved to gain 
effective biocompatibility [306]. Highly purified alginate-based materials have brought 
promising results, but capsular overgrowth is still an issue leading to inadequate blood and 
nutrients supply. Conformal coating of cells and cell clusters seems to be one possibility to 
overcome problems of cell malnutrition by reducing the distance between cells and capillaries 
and has shown better quality in terms of immunogenicity. Despite the progress achieved in 
biotechnology, the balance between immunoprotection and nutrition delivery requires further 
attention. Interestingly, necrosis of the central region of the encapsulated cells was identified in 
several studies as the common characteristic for graft failure and thus it was hypothesized that 
poor nutrition and lack of blood supply are the main causes of loss of function other than failure 
in immunoprotection [279]. 
There is no consensus about the ideal site of transplantation. Many reports gave evidence for the 
advantages of intraperitoneal placement of both encapsulated islets and hepatocytes. Peritoneum 
is well surgically accessible but the shortage of nutrition impairs the engraftment of encapsulated 
cells [307, 308]. Moreover the lack of contact with vessels causes a reduced insulin response to 
glucose stimuli for the islets. On the other hand, the om ntal pouch has shown sufficient 
angiogenesis potential and could be an ideal site for islet transplantation by virtue of direct portal 
delivery. Intraportal infusion has the advantage of providing more accessible blood supply to the 
encapsulated cells but it is affected by the risk of occlusion. Hence, optimization of the 
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microcapsule size is advised in order to avoid unnecessary hydrogel dead-volume. Islet 
encapsulated therapy has been demonstrated to be effective in the treatment of diabetes in rodent 
models and large animals. Feasibility and biocompatibility studies in human beings have recently 
highlighted the potential of this fascinating technology in translational medicine, but effective 
results in patients are still lacking [309]. However, enough evidence has been gathered to justify 
clinical trials, in particular for porcine islet xenotransplantation [310]. The other therapeutic area, 
which might largely benefit from xenotransplantation, is the reversal of acute liver failure. In 
murine models, the engraftment of encapsulated xenogenic hepatocytes brought new advances in 
cell therapy [270, 271]. Xenogeneic sources of hepatocytes should be considered in translational 
protocols given the shortage of liver donors. Further studies in large animal models are required 
to prove the effectiveness of this strategy. However, encapsulated hepatocytes have shown, by 
metabolites de-tossification rate analysis, loss of function within 30 days after transplantation. 
This short-term cell functionality could be acceptable for therapies intending to provide a bridge 
for the native liver to regenerate upon acute failure, but is objectionable for a long-term function 
protocol in order to treat chronic liver diseases. In the near future, cryopreserved 
microencapsulated cells could be stored in a cell therapy bank with the aim to secure large 
quantities for patients. Also for this purpose, alginate-based hydrogels were successfully tested. 
Cryopreservation and re-warming did not negatively affect the function of microencapsulated 
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hepatocytes [311, 312]. In conclusion, while the potential of cell microencapsulation for the 
development of cell therapies has been demonstrated in animal models, long-term studies are still 
scarcely reported. Despite promising results, translating in particular xenotransplantation of 
microencapsulated cells into a therapy will require further multidisciplinary efforts. The final 
success will not least depend on the development of suitable encapsulation materials and 
technologies. 
  
Page 36 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
37 
 
 
 
 
 
 
References 
 
1. Application of current statutory authorities to human somatic cell therapy products and gene 
therapy products, notice, Oct 14, 1993 (federal register). (Notice from the center for biologics 
evaluation and research, center for drug evaluation and research, center for devices and 
radiological health, U.S. Food and drug administration). 
2. Calafiore R, Basta G, Luca G et al. Grafts of microencapsulated pancreatic islet cells for the 
therapy of diabetes mellitus in non-immunosuppressed animals. Biotechnol Appl Biochem 2004: 
39:159-64. 
3. Tomaro-Duchesneau C, Saha S, Malhotra M et al. Microencapsulation for the therapeutic 
delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: Current status 
and future directions. J. Pharm. 2013. Article ID 103527. doi:10.1155/2013/103527 
4. Bisceglie VV. Uber die antineoplastische immunität. Krebsforsch 1933: 40: 141-158. 
5. Chang TMS. Semipermeable microcapsules. Science 1964: 146: 524-525. 
6. Rapport annuel 2012. Fondation Nationale Suisse pour le don et la transplantation d'organes. 
http://www.swisstransplant.org. 
7. Aebischer P. Transplantation in humans of encapsulated xenogeneic cells without 
immunosuppression: A preliminary report. Transplantation 1994: 58: 1275-1277. 
Page 37 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
38 
 
 
 
 
 
 
8. Bonavita AG, Quaresma K, Cotta-de-Almeida V et al. Hepatocyte xenotransplantation for 
treating liver disease. Xenotransplantation 2010: 17: 181-187. 
9. Teng Y, Wang Y, Li S et al. Treatment of acute hepatic failure in mice by transplantation of 
mixed microencapsulation of rat hepatocytes and transgenic human fetal liver stromal cells. 
Tissue Eng. Part C -meth 2010: 16: 1125-1134. 
10. Qiu L, Wang J, Wen X et al. Transplantation of co-microencapsulated hepatocytes and 
HUVECs for treatment of fulminant hepatic failure. Int. J. Artif. Organs 2012: 35: 458-465. 
11. Coussa R, Martoni C, Bhathena J et al. Oral microencapsulated live Saccharomyces 
cerevisiae cells for use in renal failure uremia: Preparation and in vivo analysis. J. Biomed. 
Biotechnol. 2010. Article ID 620827. doi:10.1155/2010/620827. 
12. Jain P, Shah S, Coussa R, Prakash S. Potentials and limitations of microorganisms as renal 
failure biotherapeutics. Biologics 2009: 3: 233-243. 
13. Brodie JC, Humes HD. Stem cell approaches for the treatment of renal failure. Pharmacol. 
Rev. 2005: 57: 299-313. 
14. Salmons B, Gunzburg WH. Therapeutic application of cell microencapsulation in cancer. 
Adv Exp Med Biol. 2010: 670: 92-103. 
15. Pareta RA. Bioartificial pancreas: Drug delivery through islet microencapsulation to treat 
diabetes. Recent patents on biomedical engineering 2012: vol 5, issue 1, p41. 
Page 38 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
39 
 
 
 
 
 
 
16. Basta G, Calafiore R. Immunoisolation of pancreatic islet grafts with no recipient's 
immunosuppression: Actual and future perspectives. Curr Diab Rep 2011: 11: 384-391. 
17. Montanucci P, Pennoni I, Pescara T, Basta G, Calafiore R. Treatment of diabetes mellitus 
with microencapsulated fetal human liver (FH-B-TPN) engineered cells. Biomaterials 2013: 34: 
4002-4012. 
18. Dufrane D, Gianello P. Macro- or microencapsulation of pig islets to cure type-1 diabetes. 
World J Gastroenterol 2012: 18 :6885-6893. 
19. Wichterle O, Lim D. Hydrophilic gels for biological use. Nature 1960: 185: 117-118. 
20. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliver Rev 2002: 54: 3-12. 
21. Censi R, Di Martino P, Vermonden T, Hennink WE. Hydrogels for protein delivery in tissue 
engineering. J Control Release 2012: 161: 680-692. 
22. Liu LS, Kost J, Yan F, Spiro RC. Hydrogels from biopolymer hybrid for biomedical, food, 
and functional food applications. Polymers 2012: 4: 997-1011. 
23. Mawad D, Boughton EA, Boughton P, Lauto A. Advances in hydrogels applied to 
degenerative diseases Curr Pharm Des. 2012: 18: 2558-2575.  
24. Seliktar D. Designing cell-compatible hydrogels for biomedical applications. Science 2012: 
336: 1124-1128. 
25. Gasperini L, Mano JF, Reis RL. Natural polymers for the microencapsulation of cells. J R 
Soc Interface. 2014: 11: 19 pages. 
Page 39 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
40 
 
 
 
 
 
 
26. Olabisi RM. Cell microencapsulation with synthetic polymers. J Biomed Mater Res Part A. 
2015: 103A: 846-859. 
27. Selimović S, Oh J, Bae H, Dokmeci M, Khademhosseini A. Microscale strategies for 
generating cell-encapsulating hydrogels. Polymers 2012: 4: 1554-1579. 
28. Billiet T, Vandenhaute M, Schelfhout J, Van Vlierberghe S, Dubruel P. A review of trends 
and limitations in hydrogel-rapid prototyping for tissue engineering. Biomaterials 2012: 33: 
6020-6041. 
29. Gauvin R, Parenteau-Bareil R, Dokmeci MR, Merryman WD, Khademhosseini A. Hydrogels 
and microtechnologies for engineering the cellular microenvironment. WIREs Nanomed 
Nanobiotechnol 2012: 4: 235-246. 
30. Borg DJ, Bonifacio E. The use of biomaterials in islet transplantation. Curr Diab Rep. 2011: 
11: 434-444. 
31. Habibi Y, Lucia LA, Rojas OJ. Cellulose nanocrystals: Chemistry, self-assembly, and 
applications. Chem. Rev. 2010: 110: 3479-3500. 
32. Keerl M, Smirnovas V, Winter R, Richtering W. Interplay between hydrogen bonding and 
macromolecular architecture leading to unusual phase behavioir in thermosensitive micirogels. 
Angew. Chem. Int. Ed 2008: 47: 338-341.  
33. Wang, H.-J.; Hong, X. Z.; Ba, X.-W. Sol-gel transition in nonlinear hydrogen bonding 
solutions Macromolecules 2007; 40, 5593-5598;  
Page 40 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
41 
 
 
 
 
 
 
34. Yilmaz Y. Transition between collapsed state phases and the critical swelling of a hydrogen 
bonding gel: poly(methacrylic acid-co-dimethyl acrylamide). J Chem Phys 2007: 126: 224501. 
35. Schneider HJ, Strongin RM. Supramolecular interactions in chemomechanical polymers. 
Acc. Chem. Res. 2009: 42: 1489-1500. 
36. Das P, Heuser T, Wolf A et al. Tough and catalytically active hybrid biofibers wet-spun from 
nanochitin hydrogels. Biomacromolecules 2012; 13: 4205-4212. 
37. Govan JRW, Fyfe JAM, Jarman TR. Isolation of alginate-producing mutants of pseudomonas 
fluorescens, pseudomonas putida and pseudomonas mendocina. J. Gen. Microbiol. 1981: 125: 
217-220. 
38. Fischer FG, Dorfel H. Die polyuronsauren der braunalgen (kohlenhydrate der algen-I). 
Hoppe-Seylers zeitschrift fur physiologische chemie 1955: 302: 186-203. 
39. Mørch YA, Donati I, Strand BL, Skjåk-Braek G. Effect of Ca
2+
, Ba
2+
, and Sr
2+ 
on alginate 
microbeads. Biomacromolecules 2006: 7: 1471-1480. 
40. Moya ML, Morley M, Khanna O, Opara EC, Brey EM. Stability of alginate microbead 
properties in vitro. J Mater Sci Mater Med 2012: 23: 903-912. 
41. Grant GT, Morris ER, Rees DA, Smith PJC, Thom D. Biological interactions between 
polysaccharides and divalent cations: The egg box model. FEBS Lett. 1973: 32: 195-198. 
42. Draget KI, Skjak-Bræek G, Smidsrød O. Alginate based new materials. Int. J. Biol. 
Macromol. 1997: 21: 47-55. 
Page 41 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
42 
 
 
 
 
 
 
43. Wandrey C, Espinosa D, Rehor A, Hunkeler D. Influence of alginate characteristics on the 
properties of multi-component microcapsules. J. Microencapsulation 2003: 20: 597-611. 
44. Espevik T, Otterlei M, Skjak-Braek G, Ryan L, Wright SD, Sundan A. The involvement of 
CD14 in stimulation of cytokine production by uronic acid polymers. Eur. J. Immunol. 1993: 23: 
255-261. 
45. Kulseng B, Skjåk-Braek G, Ryan L et al. Transplantation of alginate microcapsules: 
Generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. 
Transplantation 1999: 67: 978-984. 
46. Clayton HA, London NJM, Colloby PS, Bell PRF, James RFL. The effect of capsule 
composition on the biocompatibility of alginate-poly-l-lysine capsules. J. Microencapsulation 
1991: 8: 221-233. 
47. Montanucci P, Terenzi S, Santi C, Pennono I, Bini V, Pescara T, Basta G, Calafiore R. 
Insights in behavior of variably formulated alginate-based microcapsules for cell transplantation. 
Biomed Res Int. 2015: Article ID 965804: 11 pages. 
48. Vauchel P, Arhaliass A, Legrand J, Kaas R, Baron R. Decrease in dynamic viscosity and 
average molecular weight of alginate from Laminaria digitata during alkaline extraction. Journal 
of Phycology 2008: 44: 515-517. 
49. Mancini M, Moresi M, Sappino F. Rheological behavior of aqueous dispersions of algal 
sodium alginates. J. Food Eng 1996: 28: 283-295. 
Page 42 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
43 
 
 
 
 
 
 
50. Du XW, Wu HL, Zhu YF et al. Experimental study of therapy of bone marrow mesenchymal 
stem cells or muscle-like cells/calcium alginate composite gel for the treatment of stress urinary 
incontinence. Neurourol urodyn 2013: 32: 281-286. 
51. Potentiality of immobilized pig hepatocyte spheroids in bioartificial liver system. Transplant 
Proc 2012: 44: 1012-1014. 
52. Dufrane, D, Van Steenberghe M, Goebbels RM, Saliez A, Guiot Y, Gianello P. The influence 
of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in 
rats. Biomaterials 2006: 27: 3201-3208. 
53. Moyer HR, Kinney RC, Singh KA et al. Alginate microencapsulation technology for the 
delivery of adipose-derived stem cells. Ann. Plastic Surg 2010: 65: 497-503. 
54. Man Y, Wang P, Guo Y et al. Angiogenic and osteogenic potential of platelet-rich plasma 
and adipose-derived stem cell laden alginate microspheres. Biomaterials 2012: 33: 8802-8811. 
55. Endres M, Wenda N, Woehlecke H et al. Microencapsulation and chondrogenic 
differentiation of human mesenchymal progenitor cells from subchondral bone marrow in Ca-
alginate for cell injection. Acta Biomater. 2010: 6: 436-444. 
56. Schneider S, Feilen PJ, Brunnenmeier F et al. Long-term graft function of adult rat and 
human islets encapsulated in novel alginate-based microcapsules after transplantation in 
immunocompetent diabetic mice. Diabetes 2005: 54: 687-693. 
Page 43 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
44 
 
 
 
 
 
 
57. Malpique R, Osório LM, Ferreira DS et al. Alginate encapsulation as a novel strategy for the 
cryopreservation of neurospheres. Tissue Eng Part C Methods 2010: 16: 965-977. 
58. Penolazzi L, Tavanti E, Vecchiatini R et al. Encapsulation of Mesenchymal Stem Cells from 
Wharton's Jelly in Alginate Microbeads. Tissue Eng Part C 2010: 16: 141-155. 
59. Qi M, Mørch Y, Lacík I et al. Survival of human islets in microbeads containing high 
guluronic acid alginate crosslinked with Ca
2+ 
and Ba
2+
. Xenotransplantation 2012: 19: 355-364. 
60. Qi M, Strand BL, Mørch Y et al. Encapsulation of human islets in novel inhomogeneous 
alginate-Ca
2+
/Ba
2+
 microbeads: In vitro and in vivo function. Artif Cells Blood Substit Immobil 
Biotechnol 2008: 36: 403-420. 
61. Wikström J, Elomaa M, Syväjärvi H et al. Alginate-based microencapsulation of retinal 
pigment epithelial cell line for cell therapy. Biomaterials 2008: 29: 869-876. 
62. Smidsrød, O.; Skjak-Bræk, G. Alginate as immobilization matrix for cells. Trends Biotechnol 
1990: 8: 71-78. 
63. Lim F, Sun AM. Microencapsulated islets as bioartifical endocrine pancreas. Science 1980: 
210: 908-910. 
64. Acarregui A, Pedraz JL, Blanco FJ, Hernández RM, Orive G. Hydrogel-based scaffolds for 
enclosing encapsulated therapeutic cells. Biomacromolecules 2013: 14: 322-330. 
65. Huang X, Zhang X, Wang X, Wang C, Tang B. Microenvironment of alginate-based 
microcapsules for cell culture and tissue engineering. J. Biosci Bioeng 2012: 114: 1-8. 
Page 44 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
45 
 
 
 
 
 
 
66. Dubrot J, Portero A, Orive G et al. Delivery of immunostimulatory monoclonal antibodies by 
encapsulated hybridoma cells. Cancer Immunology, immunotherapy 2010: 59: 1621-1631. 
67. Santos E, Larzabal L, Calvo A et al. Inactivation of encapsulated cells and their therapeutic 
effects by means of TGL triple-fusion reporter/biosafety gene. Biomaterials 2013: 34:1442-1451. 
68. Santos E, Orive G, Calvo A et al. Optimization of 100 µm alginate-poly-l-lysine-alginate 
capsules for intravitreous administration. J Control Release 2012: 158: 443-450. 
69. Shanbhag MS, Lathia JD, Justin D et al. Neural progenitor cells grown on hydrogel surfaces 
respond to the product f the transgene of encapsulated genetically engineered fibroblasts. 
Biomacromolecules 2010: 2936-2943. 
70. Bhujbal SV, De Haan B, Niclou SP, De Vos P. A novel multilayer immunoisolating 
encapsulation system overcoming protusion of cells. Sci. Rep. 2014: 4: 6856: 8 pages. 
71. Rokstad AM, Brekke OL, Steinkjer B et al. Alginate microbeads are complement compatible, 
in contrast to polycation containing microcapsules, as revealed in a human whole blood model. 
Acta Biomater. 2011: 7: 2566-2578. 
72. Strand BL, Ryan TL, Kulseng B et al. Poly-L-lysine induces fibrosis on alginate 
microcapsules via the induction of cytokines. Cell Transplant 2001: 10: 263-275. 
73. Juste S, Lessard M, Henley N et al. Effect of poly-L-lysine coating on macrophage activation 
by alginate-based microcapsules: Assessment using a new in vitro method. J Biomed Mater Res 
Part A 2005: 72: 389-398. 
Page 45 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
46 
 
 
 
 
 
 
74. Nilsson B, Korsgren O, Lambris JD et al. Can cells and biomaterials in therapeutic medicine 
be shielded from innate immune recognition? Trends Immunol 2010: 31: 32-38. 
75. Ekdahl KN, Lambris, JD, Elwing H et al. Innate immunity activation on biomaterial surfaces: 
a mechanistic model and coping strategies. Adv Drug Deliv Rev 2010: 63: 1042-1050. 
76. Babensee JE, Cornelius RM, Brash JL, Sefton MV. Immunoblot analysis of proteins 
associated with HEMA-MMA microcapsules: Human serum proteins in vitro and rat proteins 
following implantation. Biomaterials 1998: 19: 839-849. 
77. Tang L, Ugarova TP, Plow EF, Eaton JW. Molecular determinants of acute inflammatory 
responses to biomaterials. J Clin Invest 1996: 97: 1329-1334. 
78. Rokstad AM, Brekke OL, Steinkjer B et al. The induction of cytokines by polycation 
containing microspheres by a complement dependent mechanism. Biomaterials 2013: 34: 621-
630. 
79. Sawhney AS, Hubbell JA. Poly(ethylene oxide)-graft-poly(L-lysine) copolymers to enhance 
the biocompatibility of poly(L-lysine)-alginate microcapsule membranes. Biomaterials 1992: 13: 
863-870. 
80. Park J-B, Jeong J-H, Lee M, Lee DY, Byun Y. Xenotransplantation of exendin-4 gene 
transduced pancreatic islets using multi-component (alginate, poly-L-lysine, and polyethylene 
glycol) microcapsules for the treatment of type 1 diabetes mellitus. J Biomater Sci Polym Ed. 
2013: 24: 2045-2057. 
Page 46 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
47 
 
 
 
 
 
 
81. Spsojevic M, Paredes-Juarez GA, Vorenkamp J, De Haan BJ, Schouten AJ, De Vos P. 
Reduction of the inflammatory responses against alginate-poly-L-lysine microcapsules by anti-
biofouling surfaces of PEG-b-PLL diblock copolymers.  PLoS ONE. 2014: 9: 11 pages. 
82. H A Clayton; Clayton HA, London NJM, Colloby PS et al. The effect of capsule composition 
on the biocompatibility of alginate-poly-l-lysine capsules. J. Microencapsulation 1991: 8: 221-
233.  
83. Robitaille R, Pariseau JF, Leblond FA et al. Studies on small (<350 µm) alginate-poly-L-
lysine microcapsules. III. Biocompatibility of smaller versus standard microcapsules. J Biomed 
Mater Res Part A 1999: 44: 116-120. 
84. King A, Strand B, Rokstad AM et al. Improvement of the biocompatibility of alginate/poly-
L-lysine/alginate microcapsules by the use of epimerized alginate as a coating. J Biomed Mater 
Res Part A 2003: 64: 533-539. 
85. Hobbs HA, Kendall WF, Darrabie M et al. Substitution of polyornithine for polylysine in 
alginate microcapsules. Diabetes 49 (suppl 1): A111. 
86. Brunetti P, Basta G, Faloerni A et al. Immunoprotection of pancreatic islet grafts within 
artificial microcapsules. Int J Artif Organs 1991: 14: 789-791. 
87. Calafiore R, Basta G, Boselli C et al. Effects of alginate/polyaminoacidic coherent 
microcapsule transplantation in adult pigs. Transplant Proc 1997: 29: 2126-2127. 
Page 47 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
48 
 
 
 
 
 
 
88. Tam SK, Bilodeau S, Dusseault J et al. Biocompatibility and physicochemical characteristics 
of alginate-polycation microcapsules. Acta Biomater. 2011: 7: 1683-1692. 
89 Darrabie MD, Kendall WF, Opara EC. Characteristics of poly-L-ornithine-coated alginate 
microcapsules. Biomaterials 2005: 26: 6846-6852. 
90. Nabavimanesh MM, Hashemi-Najafababi S, Vasheghani-Farahani E. Islets immunoisolation 
using encapsulation and PEGylation, simultaneously, as a novel design. J Biosci Bioeng. 2015: 
119: 486-491. 
91. Chen AZ, Bai Y, Wang SB, Liu YG, Chen ZX. Molecular biocompatibility evaluation of 
poly-L-ornithine-coated alginate microcapsules by investigating mRNA expression of pro-
inflammatory cytokines. J. Biomimetics Biomater. Tissue Eng 2012: 14: 53-64. 
92. Calafiore R, Basta G, Luca G et al. Transplantation of pancreatic islets contained in minimal 
volume microcapsules in diabetic high mammalians. Ann. NY Acad. Sci. 1999: 875: 219-232. 
93. Skinner SJM, Geaney MS, Lin H et al.  Encapsulated living choroid plexus cells: potential 
long-term treatments for central nervous system disease and trauma. J. Neural Eng. 2009: 6: art. 
no. 065001. 
94. Opara EC, Mirmalek-Sani SH, Khanna O, Moya ML, Brey EM. Design of a bioartificial 
pancreas(+). J. Invest. Med. 2010: 58: 831-837.  
95. S J M Skinner. Journal of Neural Engineering Volume 6 Number 6 art. no. 065001 
Page 48 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
49 
 
 
 
 
 
 
96. Terbojevich M, Muzzarelli RAA R. Chitosan. In: Phillips, G. O. and Williams, P. A. (Eds.). 
Handbook of Hydrocolloids 2000: 367-378. Cambridge: Woodhead Publishing Ltd. 
97. Li S, Zhang Y, Chen L, Li N, Xie H, Guo X, Zhao S, Yu W, Lv Y, Lv G, Wu H, Ma X. The 
relationship between the inflammatory reponse and cell adhesion on alginate-chitosan-alginate 
microcapsules after transplantation. J Biomed Mater Res Part A. 2014: 103A: 2333-2343. 
98. Huguet ML, Dellacherie E. Calcium alginate beads coated with chitosan: effect of the 
structure of encapsulated Materials on their release. Process Biochem 1996: 31: 745-751 
99. Daly MM, Knorr D. Chitosan–alginate complex coacervate capsules: effects of calcium 
chloride, plasticizers, and polyelectrolytes on mechanical stability. Biotechnol Prog 1988: 4: 76-
81. 
100. Zhao W, Zhang Y, Liu Y et al. Oxygen diffusivity in alginate/chitosan microcapsules. J. 
Chem. Technol. Biotechnol. 2012: 88: 449-455. 
101. Bartkowiak A, Lisiecki S, Orive G, Pedraz JL. The effect of selected parameters of 
formation on properties of alginate/Ca
2+
/oligochitosan capsules. J. Chem. Technol. Biotechnol. 
2006: 81: 511-518. 
102. Baruch L, Machluf M. Alginate-chitosan complex coacervation for cell encapsulation: 
Effect on mechanical properties and on long-term viability. Biopolymers 2006: 82: 570-579. 
103. Orive G, Bartkowiak A, Lisiecki S et al. Biocompatible oligochitosan as cationic modifiers 
of alginate/Ca microcapsules. J Biomed Mater Res B Appl Biomater. 2005: 74: 429-439. 
Page 49 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
50 
 
 
 
 
 
 
104. Gåserød O, Smidsrød O, Skjåk-Braek G. Microcapsules of alginate-chitosan-I: A 
quantitative study of the interaction between alginate and chitosan. Biomaterials 1998: 19: 1815-
1825. 
105. Gåserød O, Sannes A, Skjåk-Braek G. Microcapsules of alginate–chitosan-II. A study of 
capsule stability and permeability. Biomaterials 1999: 20: 773-783. 
106. Zheng J, Xie H, Yu W et al. Enhancement of surface graft density of MPEG on 
alginate/chitosan hydrogel microcapsules for protein repellency. Langmuir 2012: 28: 13261-
13273. 
107. Roshanbinfar K, Salahshour Kordestani S, Encapsulating beta islet cells in alginate, 
alginate-chitosan and alginate-chitosan-PEG microcapsules and investigation of insulin secretion. 
Journal of Biomaterials and Tissue Engineering 2013: 3: 185-189. 
108. Zhi ZL, Kerby A, King AJ, Jones PM, Pickup JC. Nano-scale encapsulation enhances 
allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia 
2012: 55: 1081-1090. 
109. Kim SK, Lee JH, Lee DH, Park JK. Optimization of chitosan-alginate encapsulation process 
using pig hepatocytes for development of bioartificial liver. J. Microbiol. Biotechnol. 2005: 15: 
7-13. 
Page 50 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
51 
 
 
 
 
 
 
110. Haque T, Chen H, Ouyang W et al. In vitro study of alginate-chitosan microcapsules: An 
alternative to liver cell transplants for the treatment of liver failure. Biotechnol Lett. 2005: 27: 
317-322. 
111. Son JH, Ha YM, Kim YI et al. Immobilization of cryopreserved primary rat hepatocytes for 
the development of a bioartificial liver system. Biotechnol Lett. 2006: 28: 51-54. 
112. Seo SJ, Kim IY, Choi YJ, Akaike T, Cho CS. Enhanced liver functions of hepatocytes 
cocultured with NIH 3T3 in the alginate/galactosylated chitosan scaffold. Biomaterials 2006: 27: 
1487-1495. 
113. Chen F, Tian M, Zhang D et al. Preparation and characterization of oxidized alginate 
covalently cross-linked galactosylated chitosan scaffold for liver tissue engineering. Mater. Sci. 
Eng., C 2012: 32: 310-320. 
114. Lv G, Zhao L, Zhang A et al. Bioartificial liver system based on choanoid fluidized bed 
bioreactor improve the survival time of fulminant hepatic failure pigs. Biotechnol. Bioeng. 2011: 
108: 2229-2236. 
115. Forsey RW, Tare R, Oreffo ROC, Chaudhuri JB. Perfusion bioreactor studies of 
chondrocyte growth in alginate–chitosan capsules. Biotechnol. Appl. Biochem. 2012: 59: 142-
152. 
Page 51 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
52 
 
 
 
 
 
 
116. Kuo YC, Wang CC. Guided differentiation of induced pluripotent stem cells into neuronal 
lineage in alginate-chitosan-gelatin hydrogels with surface neuron growth factor. Colloids Surf B 
Biointerfaces. 2013: 104: 194-199. 
117. Renken A, Hunkeler D. Polymethylene-co-guanidine based capsules: A mechanistic study 
of the formation using alginate and cellulose sulphate. J. Microencapsulation 2007: 24: 20-39.  
118. Wandrey C, Espinosa D, Rehor A, Hunkeler D. Influence of alginate characteristics on the 
properties of multi-component microcapsules. J. Microencapsulation 2003: 20: 597-611. 
119. Schuldt U, Hunkeler D. Alginate-cellulose sulphate-oligocation microcapsules: optimization 
of mass transport and mechanical properties. J Microencapsulation 2007: 24: 1-10. 
120. Lacík I, Anilkumar AV, Wang TG. A two-step process for controlling the surface 
smoothness of polyelectrolyte-based microcapsules. J. Microencapsulation 2001: 18: 479-490. 
121. Canaple L, Nurdin N, Angelova N, Hunkeler D, Desvergne B. Development of a coculture 
model of encapsulated cells. Ann. N.Y. Acad. Sci. 2001: 944: 350-361. 
122. Zhang LY, Yao SJ, Guan YX. Diffusion characteristics of solutes with low molecular 
weight in sodium alginate/cellulose sulfate-CaCl2/poly(methylene-co-guanidine) capsules. J. 
Chem. Eng. Data 2003: 48: 864-868. 
123. Zhang LY, Yao SJ, Guan YX. Effects of poly(methylene-co-guanidine) on microbial growth 
in an alginate/cellulose sulphate-CaCl2/poly(methylene-co-guanidine) capsule system. Process 
Biochem. 2005: 40: 189-193. 
Page 52 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
53 
 
 
 
 
 
 
124. Nahalka J, Dib I, Nidetzky B. Encapsulation of Trigonopsis variabilis D-amino acid oxidase 
and fast comparison of the operational stabilities of free and immobilized preparations of the 
enzyme. Biotechnol Bioeng. 2008: 99: 251-260. 
125. Vikartovská A, Bučko M, Mislovičová D et al. Improvement of the stability of glucose 
oxidase via encapsulation in sodium alginate-cellulose sulfate-poly(methylene-co-guanidine) 
capsules. Enzyme Microb. Technol. 2007: 41: 748-755. 
126. Klouda L, Mikos AG. Thermoresponsive hydrogels in biomedical applications. Eur. J. 
Pharm. Biopharm. 2008: 68: 34-45. 
127. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical 
formulations. Eur. J. Pharm. Biopharm. 2000: 50: 27.46. 
128. Patel A, Mequanint K. Hydrogel Biomaterials. In: Biomedical engineering-Frontiers and 
challenges, ISBN 979-953-307-028-4, Chapter 14, 275-296, 2011. 
129. Stabenfeldt SE, García AJ, LaPlaca MC. Thermoreversible laminin-functionalized hydrogel 
for neural tissue engineering. J Biomed Mater Res Part A 2006: 77A: 718-725. 
130. Zan J, Chen H, Jiang G, Lin Y, Ding F. Preparation and properties of crosslinked chitosan 
thermosensitive hydrogel for injectable drug delivery systems. J. Appl. Polym. Sci. 2006: 101: 
1892-1898. 
131. Lu X, Hu Z, Gao J. Synthesis and light scattering study of hydroxypropyl cellulose 
microgels. Macromolecules 2000: 33: 8698-8702. 
Page 53 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
54 
 
 
 
 
 
 
132. Kim JH, Lee SB, Kim SJ, Lee YM. Rapid temperature/pH response of porous alginate-g-
poly(N-isopropylacrylamide) hydrogels. Polymer 2002: 43: 7549-7558 
133. Schmaljohann D. Thermo-responsive polymers and hydrogels in tissue engineering. E-
Polymers 2005: no. 021 
134. Tan H, Ramirez CM, Miljkovic N et al. Thermosensitive injectable hyaluronic acid hydrogel 
for adipose tissue engineering. Biomaterials 2009: 30: 6844-6853. 
135. Suwa K, Wada Y, Kishida A, Akashi M. Synthesis and functionalities of poly(N-
vinylalkylamide). VI. A n vel thermosensitive hydrogel crosslinked poly(N-vinylisobutyramide). 
J. Polym. Sci., Part A: Polym. Chem. 1997: 35: 3377-3384. 
136. Peroglio M, Grad S, Mortisen D et al. Injectable thermoreversible hyaluronan-based 
hydrogels for nucleus pulposus cell encapsulation. Eur Spine J. 2012: 21: 839-849. 
137. Eeckman F, Amighi K, Moës AJ. Effect of some physiological and non-physiological 
compounds on the phase transition temperature of thermoresponsive polymers intended for oral 
controlled-drug delivery. Int J Pharm. 2001: 222: 259-270. 
138. Rollason G, Davies JE, Sefton MV. Preliminary report on cell culture on a thermally 
reversible copolymer. Biomaterials 1993: 14: 153-155. 
139. Park TG, Hoffman AS. Estimation of temperature-dependent pore size in poly(N-
isopropylacrylamide) hydrogel beads. Biotechnol Prog. 1994: 10: 82-86. 
Page 54 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
55 
 
 
 
 
 
 
140. Desai RM, Koshy ST, Hilderband SA, Mooney DJ, Joshi NS. Versatile click alginate 
hydrogels crosslinked via tetrazine-norbornene chemistry. Biomaterials. 2015: 50: 30-37. 
141. Xu K, Fu Y, Chung W. Thiol-ene-based biological/synthetic hybrid biomatrix for 3-D living 
cell culture. Acta Biomater. 2012: 8: 2504-2516. 
142. Fu Y, Xu K, Zheng X et al. 3D cell entrapment in crosslinked thiolated gelatin-
poly(ethylene glycol) diacrylate hydrogels. 2012 Biomaterials 2012: 33: 48-58. 
143. Phelps EA, Enemchukwu NO, Fiore VF et al. Maleimide cross-linked bioactive PEG 
hydrogel exhibits improved reaction kinetics and cross-linking for cell encapsulation and in situ 
delivery. Adv. Mater. 2012: 24: 64-70. 
144. Almany L, Seliktar D. Biosynthetic hydrogel scaffolds made from fibrinogen and 
polyethylene glycol for 3D cell cultures. Biomaterials 2005: 26: 2467-2477. 
145. Cho NJ, Elazar M, Xiong A et al. Viral infection of human progenitor and liver-derived cells 
encapsulated in 3D PEG-based hydrogel. Biomed. Mater. 2009: 4: 011001 
146. Hong Y, Song HQ, Gong YH et al. Covalently crosslinked chitosan hydrogel: Properties of 
in vitro degradation and chondrocyte encapsulation. Acta Biomater. 2007: 3: 23-31. 
147. Hu X, Li D, Gao C. Chemically cross-linked chitosan hydrogel loaded with gelatin for 
chondrocyte encapsulation. Biotechnol. J. 2011: 6: 1388-1396. 
Page 55 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
56 
 
 
 
 
 
 
148. Tan H, Chu CR, Payne KA, Marra KG. Injectable in situ forming biodegradable chitosan–
hyaluronic acid based hydrogels for cartilage tissue engineering. Biomaterials 2009: 30: 2499-
2506. 
149. Brunsen A, Ritz U, Mateescu A et al. Photocrosslinkable dextran hydrogel films as 
substrates for osteoblast and endothelial cell growth. J. Mater. Chem. 2012: 22: 19590-19604. 
150. Liu Y, Chan-Park MB. A biomimetic hydrogel based on methacrylated dextran-graft-lysine 
and gelatin for 3D smooth muscle cell culture. Biomaterials 2010: 31: 1158-1170. 
151. Ferreira LS, Gerecht S, Fuller J et al. Bioactive hydrogel scaffolds for controllable vascular 
differentiation of human embryonic stem cells. Biomaterials 2007: 28: 2706-2717.  
152. Choh SY, Cross D, Wang C. Facile synthesis and characterization of disulfide-cross-linked 
hyaluronic acid hydrogels for protein delivery and cell encapsulation. Biomacromolecules 2011: 
12: 1126-1136 
153. Bian L, Hou C, Tous E. The influence of hyaluronic acid hydrogel crosslinking density and 
macromolecular diffusivity on human MSC chondrogenesis and hypertrophy. Biomaterials 2013: 
34: 413-421. 
154. Darr A, Calabro A. Synthesis and characterization of tyramine-based hyaluronan hydrogels. 
J. Mater. Sci. Mater. Med. 2009: 20: 33-44. 
155. Flynn L, Prestwich GD, Semple JL, Woodhouse KA. Adipose tissue engineering with 
naturally derived scaffolds and adipose-derived stem cells. Biomaterials 2007: 28: 3834-3842. 
Page 56 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
57 
 
 
 
 
 
 
156. Young CJ, Poole-Warren LA, Martens PJ. Combining submerged electrospray and UV 
photopolymerization for production of synthetic hydrogel microspheres for cell encapsulation. 
Biotechnol. Bioeng. 2012: 109: 1561-1570. 
157. Alves MH, Young CJ, Bozzetto K, Poole-Warren LA, Martens PJ. Degradable, click 
poly(vinyl alcohol) hydrogels: characterization of degradation and cellular compatibility. 
Biomed. Mater. 2012: 7: no. 024106 
158. Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue 
engineering applications. Tissue Eng. Part B 2008: 14: 149-165. 
159. Schmidt JJ, Rowley J, Kong HJ. Hydrogels used for cell-based drug delivery. J. Biomed. 
Mater. Res. A 2008: 87: 1113-1122. 
160. Dusseault J, Leblond FA, Robitaille R et al. Microencapsulation of living cells in semi-
permeable membranes with covalently cross-linked layers. Biomaterials 2005: 26: 1515-1522. 
161. Gardner CM, Potter MA, Stöver HDH. Improving covalent cell encapsulation with 
temporarily reactive polyelectrolytes. J Mater Sci: Mater Med. 2012: 23: 181-193. 
162. Mazumder MAJ, Burke NAD, Shen F, Potter MA, Stöver HDH. Core-cross-linked alginate 
microcapsules for cell encapsulation. Biomacromolecules 2009: 10: 1365-1373. 
163. Hillberg AL, Oudshoorn M, Lam JBB, Kathirgamanathan K. Encapsulation of porcine 
pancreatic islets within an immunoprotective capsule comprising methacrylated glycol chitosan 
and alginate. J Biomed Mater Res Part B. 2015: 103B: 503-518. 
Page 57 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
58 
 
 
 
 
 
 
164. Mazumder MAJ, Shen F, Burke NAD, Potter MA, Stöver HDH. Self-crosslinking 
polyelectrolyte complexes for therapeutic cell encapsulation. Biomacromolecules, 2008: 9: 2292-
2300. 
165. Gardner CM, Stöver HDH. Reactive polyanions based on poly(4,4-dimethyl-2-vinyl-2-
oxazoline-5-one-co-methacrylic acid). Macromolecules, 2011: 44: 7115-7123. 
166. Chen H, Ouyang W, Martoni C. Investigation of genipin cross-linked microcapsule for oral 
delivery of live bacterial cells and other biotherapeutics: Preparation and in vitro analysis in  
simulated human gastrointestinal model. Int. J. Polym. Sci 2010: Article ID 985137, 
doi:10.1155/2010/985137 
167. Nayak S, Dey S, Kundu SC. Silk sericin-alginate-chitosan microcapsules: Hepatocytes 
encapsulation for enhanced cellular functions. Int J Biol Macromol. 2014: 65: 258-266. 
168. Mahou R, Wandrey C. Alginate-poly(ethylene glycol) hybrid microspheres with adjustable 
physical properties. Macromolecules 2010: 43: 1371-1378. 
169. Mahou R, Kolláriková G, Gonelle-Gispert C, Meier R, Schmitt F, Tran NM, Dufresne M, 
Altimari I, Lacík I, Bühler L, Juillerat-Jeanneret  L, Legallais C, Wandrey C. Combined 
electrostatic and covalent polymer networks for cell microencapsulation. Macromol Symp. 2013: 
329: 49-57. 
170. Mahou R, Meier RPH, Bühler L, Wandrey C. Alginate-poly(ethylene glycol)hybrid 
microspheres for primary cell microencapsulation. Materials. 2014: 7: 275-286. 
Page 58 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
59 
 
 
 
 
 
 
171. Gattás-Asfura K, Stabler CL. Chemoselective cross-linking and functionalization of alginate 
via Staudinger ligation. Biomacromolecules 2009: 10: 3122-3129. 
172. Hall KK, Gattás-Asfura K, Stabler CL. Microencapsulation of islets within 
alginate/poly(ethylene glycol) gels cross-linked via Staudinger ligation. Acta Biomater. 2011: 7: 
614-624.  
173. Gattás-Asfura K, Fraker CA, Stabler CL. Perfluorinated alginate for cellular encapsulation. 
J. Biomed. Mater. Res. Part A 2012: 100A: 1963-1971. 
174. Gattás-Asfura KM, Valdes M, Celik E, Stabler CL. Covalent layer-by-layer assembly of 
hyperbranched polymers on alginate microcapsules to impart stability and permselectivity. J 
Mater Chem B. 2014: 2: 8208-8219. 
175. Mahou R, Wandrey C. Versatile route to synthesize heterobifunctional poly(ethylene glycol) 
of variable functionality for subsequent pegylation. Polymers 2012: 4: 561-589. 
176. Mahou R,  Borcard F, Crivelli V, Montanari, E, Passemard S, Noverraz F, Gerber-Lemaire 
S, Bühler L, Wandrey C. Tuning the properties of hydrogel microspheres by adding chemical 
cross-linking functionality to sodium alginate. Chem Mater. 2015: 27: 4380-4389. 
177. Mahou R, Mai NT, Dufresne, M, Legallais C, Wandrey C. Encapsulation of Huh-7 cells 
within alginate-poly(ethylene glycol) hybrid microspheres. J. Mater. Sci. Mater. Med. 2012: 23: 
171-179. 
Page 59 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
60 
 
 
 
 
 
 
178. Lau HK, Kiick KL. Opportunities for multicomponent hybrid hydrogels in biomedical 
applications. Biomacromol. 2015: 16: 28-42. 
179. Tian M, Han B, Tan H, You C. Preparation and characterization of galactosylated alginate-
chitosan oligomer microcapsule for hepatocytes microencapsulation. Carbohydr Polym. 2014: 
112: 502-511. 
180. Grigore A, Sarker B, Fabry B, Boccaccini AR, Detsch R. Behavior of encapsulated MG-63 
cells in RGD and gelatine-modified alginate hydrogels. Tissue eng. 2014: 20: 2140-2150. 
181. Weber LM, Hayda KN, Haskins K, Anseth KS. The effects of cell-matrix interactions on 
encapsulated β-cell function within hydrogels functionalized with matrix-derived adhesive 
peptides. Biomaterials. 2007, 28, 3004-3011. 
182. Kim J-S, Lim J-H, Nam H-Y, Lim H-J, Shin J-S, Shin J-Y, Ryu J-H, Kim K, Kwon I-C, Jin 
S-M, Kim H-R, Kim S-J, Park C-G. In situ application of hydrogel-type fibrin-islet composite 
optimized for rapid glycemic control by subcutaneous xenogeneic porcine islet transplantation. J 
Control Release. 2012: 162: 382-390. 
183. Capone SH, Dufresne M, Rechel M, Fleury M-J, Salsac A-V, Paullier P, Daujat-Chavanieu 
M, Legallais C. Impact of alginate composition: from bead mechanical properties to encapsulated 
HepG2/C3A cell activities for in vivo implantation. PLoS ONE. 2013: 8: 10 pages. 
Page 60 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
61 
 
 
 
 
 
 
184. Campanha-Rodrigues AL, Grazioli G, Oliveira TC, Campos-Lisbôa ACV, Mares-Guia TR, 
Sogayar MC. Therapeutic potential of laminin-biodritin microcapsules for type 1 diabetes 
mellitus. Cell Transplant. 2015: 24: 247-261. 
185. Sigrist S, Mechine-Neuville A, Mandes K, Calenda V, Braun S,  Legeay G, Bellocq J-
P,  Pinget M, Kessler L. Influence of VEGF on the Viability of Encapsulated Pancreatic Rat 
Islets After Transplantation in Diabetic Mice.  Cell Transplant. 2002: 12: 627-635. 
186. Moya ML,Garfinkel MR, Liu X, Lucas S, Opara C, Greisler HP, Brey EM. Fibrobalst 
Growth Factor-1 (FGF-1) loaded microbeads enhance local capillary neovascularization. J 
Surgical Res 2009: 160: 208-212.  
187. Luan NM, Iwata H. Xenotransplantation of islets enclosed in agarose microcapsule carrying 
soluble complement receptor 1. Biomaterials. 2012: 33: 8075-8081. 
188. Chen T, Yuan J, Duncanson S, Hibert ML, Kodish BC, Mylavaganam G, Maker M, Li H, 
Sremac M, Santosuosso M, Forbes B, Kashiwagi S, Cao J, Lei J, Thomas M, Hartono C, Sachs 
D, Markmann J, Sambanis A, Poznansky 
MC. Alginate encapsulant incorporating CXCL12 supports long-term allo and xenoislet 
transplantation without systemic immune suppression. Am J Tranplant. 2015: 15: 618-627. 
189. Acarregui A, Herrán E, Igartua M, Blanco F, Pedraz JL, Orive G, Hermandez RM. 
Multifunctional hydrogel-based scaffold for improving the functionality of encapsulated 
therapeutic cells and reducing inflammatory response. Acta Biomater. 2014: 10: 4206-4216. 
Page 61 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
62 
 
 
 
 
 
 
190. Li C-C, Metters AT, Anseth KS. Functional PEG-peptide hydrogels to modulate local 
inflammation induced by the proinflammatory cytokine TNFα. Biomaterials. 2009: 30: 4907-
4914. 
191. Su J, Hu B-H, Lowe WL, Kaufman DB, Messersmith PB. Anti- imflammatory peptide-
functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials. 2010: 31: 308-
314. 
192. Thu B, Bruheim P, Espevik T et al. Alginate polycation microcapsules: I. Interaction 
between alginate and polycation. Biomaterials 1996: 17: 1031-1040. 
193. Skarja GA, Kinlough-Rathbone RL, Perry DW, Rubens FD, Brash JL. A coneand- plate 
device for the investigation of platelet biomaterial interactions. J. Biomed. Mater. Res. 1997: 34: 
427-438. 
194. Rosiński S, Grigorescu G, Lewińska D et al. Characterization of microcapsules: 
recommended methods based on round robin testing. J. Microencapsulation 2002:19: 641-659. 
195. Drury JL, Dennis RG, Mooney DJ. The tensile properties of alginate hydrogels. 
Biomaterials 2004: 25: 3187-3199. 
196. Jeffrey L, Hinkley A, Morgret LD, Gehrke SH. Tensile properties of two responsive 
hydrogels. Polymer 2004: 45: 8837-8843. 
Page 62 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
63 
 
 
 
 
 
 
197. Ahearne M, Yang Y, El Haj AJ, Then KY, Liu KK. Characterizing the viscoelastic 
properties of thin hydrogel-based constructs for tissue engineering applications. J R Soc Interface 
2005: 2: 455-463. 
198. Lewińska D, Rosiński S, Hunkeler D, Poncelet D, Weryński A. Mass transfer coefficient in 
characterization of gel beads and microcapsules. J. Membr. Sci. 2002: 209: 533-540. 
199. Li RH, Altreuter DH, Gentile FT. Transport characterization of hydrogel matrices for cell 
encapsulation. Biotechnol. Bioeng. 1996: 50: 365-373. 
200. Schuldt U, Hunkeler D. Characterization methods for microcapsules. Minerva 
Biotechnologica 2000: 12: 249-264. 
201. Uludag H, De Vos P, Tresco PA. Technology of mammalian cell encapsulation. Adv. Drug. 
Deliv. Rev. 2000: 42: 29-64. 
202. Brissova M, Petro M, Lacik I, Powers AC, Wang T. Evaluation of microcapsule 
permeability via inverse size exclusion chromatography. Anal. Biochem. 1996: 242: 104-111. 
203. Brissova M, Lacik I, Powers AC, Anilkumar AV, Wang T. Control and measurement of 
permeability for design of microcapsule cell delivery system. J. Biomed. Mater. Res. 1997: 39: 
61-70. 
204. Bertz A, Wöhl-Bruhn S, Miethe S et al. Encapsulation of proteins in hydrogel carrier 
systems for controlled drug delivery: Influence of network structure and drug size on release rate. 
J Biotechnol. 2013: 163: 243-249. 
Page 63 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
64 
 
 
 
 
 
 
205. Williams D. Revisiting the definition of biocompatibility. Med Device Technol. 2003: 14: 
10-13. 
206. Williams DF. Summary and definitions. In: Progress in biomedical engineering: Definition 
in biomaterials (4). Elsevier Science Publisher BV; 1987. p. 66–71. 
207. Sawhney AS, Hubbell JA. Poly(ethylene oxide)-graft-poly(L-lysine) copolymers to enhance 
the biocompatibility of poly(L-lysine)alginate microcapsule membranes. Biomaterials 1992: 13: 
863-870. 
208. Auchincloss H, Sachs DH. Xenogeneic transplantation. Annu. Rev. Immunol. 1998: 16: 
433-470. 
209. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant 
rejection. N. Engl. J. Med. 1998: 338: 1813-1821. 
210. Kulseng B, Skjåk-Braek G, Ryan L et al. Transplantation of alginate microcapsules: 
Generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. 
Transplantation 1999: 67: 978-984. 
211. Bhujbal SV, Paredes-Juarez GA, Niclou SP, De Vos P. Factors influencing the mechanical 
stability of alginate beads applicable for immunoisolation of mammalian cells. J Mech Behav 
Biomed Mater. 2014: 37: 196-208. 
Page 64 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
65 
 
 
 
 
 
 
212. Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR, Li J, Langan E, Wyckoff J, 
Loo WS, Jhunjhunwala S, Chiu A, Siebert S, Tang K, Hollister-Lock J, Aresta-Dasilva S, 
Bochenek M, 
Mendoza-Elias J, Wang Y, Qi M, Lavin DM, Chen M, Dholakia N, Thakrar R, Lacík I, Weir GC, 
Oberholzer J, Greiner DL, Langer R, Anderson 
DG. Size- and shape-dependent foreign body immune response to materials implanted in rodents 
and non-human primates. Nat Mater. 2015: 14: 643-651. 
213. Dulieu C, Poncelet, D.; Neufeld, R. J. Ed. W.M. Kühteriber, R. P. Lanza and W. L. Chick. 
Birkhäuser: Boston (1999): 3-17. 
214. Angelova N, Hunkeler D. Rationalizing the design of polymeric biomaterials. Trends. 
Biotechnol. 1999: 17: 409-421. 
215. De Vos P, De Haan B, Pater J, Van Schilfgaarde R. Association between capsule diameter, 
adequacy of encapsulation, and survival of microencapsulated rat islet allografts. Transplantation 
1996: 62: 893-899. 
216. Ceausoglu I, Hunkeler D. A new microencapsulation device for controlled membrane and 
capsule size distributions. J. Microencapsulation 2002: 19: 725-735. 
217. Vidal-Serp DS. Polyelectrolytes-based immunoprotection systems: polymer purification and 
surface analysis. Thesis EPFL N° 3053, 2004. 
Page 65 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
66 
 
 
 
 
 
 
218. Yu J, Wu P-C, Huang C-H, Yang C-Y, Cheng C-M. High-throughput physically based 
approach for mammalian cell encapsulation. Appl Phys Lett. 2013: 103: 153704. 
219. Heinzen C, Marison I, Berger A, von Stockar U. Use of vibration technology for jet break-
up for encapsulation of cells, microbes and liquids in monodisperse microcapsules. In 
Landbauforschung Voelkenrode, Sonderheft, num. 241 (Practical aspects of encapsulation 
technologies), p. 19-25, 2002. 
220. Hallé JP, Leblond FA, Pariseau JF et al. Studies on small (<300 µm) microcapsules II: 
Parameters governing the production of alginate beads by high voltage electrostatic pulses. Cell 
Transplant 1994: 3: 365-372. 
221. Gryshkov O, Pogozhykh D, Hofmann N, Pogozhykh O, Mueller  T, Glasmacher B. 
Encapsulating non-human primate multipotent stromal cells in alginate via high voltage for cell-
based therapies and cryopreservation. PLoS ONE. 2014: 9: 9: e107911: 12 pages. 
222. Poncelet D, Babak V, Dulieu C, Picot A. A physico-chemical approach to production of 
alginate beads by emulsification-internal ionotropic gelation. Colloids Surf. A 1999: 155: 171-
176. 
223. Poncelet D, Neufeld R, Bugarsk B et al. A Parallel plate electrostatic droplet generator: 
Parameters affecting microbead size. Appl. Microbiol. Biotechnol. 1994: 42: 251-255. 
224. Brandenberger H, Widmer F. A new multinozzle encapsulation/immobilization system to 
produce uniform beads of alginate. J Biotechnol 1998: 63: 73-80. 
Page 66 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
67 
 
 
 
 
 
 
225. Prüße U, Fox B, Kirchhoff M et al. New process (jet cutting method) for the production of 
spherical beads from highly viscous polymer solutions. Chem. Eng. Technol. 1998: 21: 29-33. 
226. Poncelet D, Lencki R, Beaulieu C et al. Production of alginate beads by emulsification / 
internal gelation. I. Methodology. Appl. Microbiol. Biotechnol. 1992: 38: 39-45. 
227. Rabanel JM, Banquy X, Zouaoui H, Mokhtar M, Hildgen P. Progress technology in 
microencapsulation methods for cell therapy Biotechnol Prog. 2009: 25: 946-963. 
228. Mazzitelli, S., Capretto, L., Quinci, F., Piva, R. & Nastruzzi, C. Preparation of cell-
encapsulation devices in confined microenvironment. Advanced Drug Delivery Reviews 2013: 
65: 1533–1555. 
229. Kang, A., Park, J., Ju, J., Jeong, G. S. & Lee, S.-H. Cell encapsulation via 
microtechnologies. Biomaterials 2014: 35: 2651–2663. 
230. Kim, C., Park, J. & Kang, J. Y. A microfluidic manifold with a single pump system to 
generate highly mono-disperse alginate beads for cell encapsulation. Biomicrofluidics 2014: 8: 
066504. 
231. Chau, M. et al. Microfluidic Generation of Composite Biopolymer Microgels with Tunable 
Compositions and Mechanical Properties. Biomacromolecules 2014: 15: 2419–2425. 
 
232. Wan J, Microfluidic-based synthesis of hydrogel particles for cell microencapsulation and 
cell-based drug delivery. Polymers 2012: 4: 1084-1108. 
Page 67 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
68 
 
 
 
 
 
 
233. Seo M, Nie Z, Xu S et al. Continuous microfluidic reactors for polymer particles. Langmuir 
2005: 21: 11614-11622. 
234. Dendukuri D, Pregibon DC, Collins J, Hatton TA, Doyle PS. Continuous-flow lithography 
for high-throughput microparticle synthesis. Nat. Mater. 2006: 5: 365-369. 
235. Kintses B, Van Vliet LD, Devenish SRA, Holfelder F. Microfluidic droplets: New 
integrated work-flows for biological experiments. Curr. Opin. Chem. Biol. 2010: 14: 548-555. 
236. Khan, I. U. et al. Microfluidic conceived drug loaded Janus particles in side-by-side 
capillaries device. Int. J. Pharm. 2014: 473: 239–249 
237. Mazutis, L., Vasiliauskas, R. & Weitz, D. A. Microfluidic Production of Alginate Hydrogel 
Particles for Antibody Encapsulation and Release. Macromol. Biosci. 2015: 
doi:10.1002/mabi.201500226 
238. Utech, S. et al. Microfluidic Generation of Monodisperse, Structurally Homogeneous 
Alginate Microgels for Cell Encapsulation and 3D Cell Culture. Adv. Healthcare Mater. 2015: 4: 
1628–1633. 
239. Allazetta, S., Hausherr, T. C. & Lutolf, M. P. Microfluidic Synthesis of Cell-Type-Specific 
Artificial Extracellular Matrix Hydrogels. Biomacromolecules 2013: 14: 1122–1131. 
240. Luo RC, Chen CH. Structured microgels through microfluidic assembly and their 
biomedical applications. SciRes Soft 2012: 1: 1-23. 
Page 68 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
69 
 
 
 
 
 
 
241. Shim TS, Kim SH, Yang SM, Elaborate design strategies toward novel microcarriers for 
controlled encapsulation and release. Part. Part. Syst. Char. 2013: 30: 9-45. 
242. Garstecki P, Fuerstman MJ, Stoen HA, Whiteside GM. Formation of droplets and bubbles in 
a cicrofluidic T-junction-scaling and mechanism of break-up. Lab Chip 2006: 6: 437-446. 
243. Baroud CN, Gallaire F, Dangla R. Dynamics of microfluidic droplets. Lab Chip 2010: 10: 
2032-2045. 
244. Nie ZH, Seo MS, Xu SQ et al. Emulsification in a microfluidic flow-focusing device: Effect 
of the viscosities of the liquids. Microfluid Nanofluidics 2008: 5: 585-594. 
245. Microfluidic fabrication of self-assembled peptide-polysaccharide microcapsules as 3D 
environments for Cell Culture 2012;  
246. Generation of disk-like hydrogel beads for cell encapsulation and manipulation using a 
droplet-based microfluidic device 2012;  
247. Dalle P, Morales S, Berthier J et al. New microfluidic chip for the production of spherical 
gelled capsules for cell encapsulation. Technical Proceedings of the 2012 NSTI Nanotechnology 
Conference and Expo, NSTI-Nanotech 2012: 298-301. 
248. Martinez CJ, Kim JW, Ye C et al. A microfluidic approach to encapsulate living cells in 
uniform alginate hydrogel microparticles. Macromol Biosci. 2012: 12: 946-951.  
249. Velasco D, Tumarkin E, Kumacheva E. Microfluidic encapsulation of cells in polymer 
microgels. Small 2012: 8: 1633-1642.  
Page 69 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
70 
 
 
 
 
 
 
250. Rossow T, Heyman JA, Ehrlicher AJ et al. Controlled synthesis of cell-laden microgels by 
radical-free gelation in droplet microfluidics. J Am Chem Soc 2012: 134:4983-4989 
251. Headen DM, Aubry G, Lu H, García AJ. Microfluidic-Based Generation of Size-Controlled, 
Biofunctionalized Synthetic Polymer Microgels for Cell Encapsulation. Adv. Mater. 2014: 26: 
3003–3008. 
252. Akbari S, Pirbodaghi T. Microfluidic encapsulation of cells in alginate particles via an 
improved internal gelation approach. Microfluid Nanofluid 2013: 16: 773–777. 
253. Wu L, Chen P, Dong Y, Feng X, Liu BF. Encapsulation of single cells on a microfluidic 
device integrating droplet generation with fluorescence-activated droplet sorting. Biomed 
Microdevices 2013: 15: 553–560. 
254. Tendulkar S, Mirmalek-Sani SH, Childers C et al. A three-dimensional microfluidic 
approach to scaling up microencapsulation of cells. Biomed Microdevices. 2012: 14: 461-469. 
255. Wilson JT, Cui W, Chaikof EL. Layer-by-layer assembly of a conformal nanothin PEG 
coating for intraportal islet transplantation. Nano Lett. 2008: 8: 1940-1948. 
256. Sefton MV, May MH, Lahooti S, Babensee JE. Making microencapsulation work: 
conformal coating, immobilization gels and in vivo performance J. Controlled Release 2000: 65: 
173-186. 
257. Wyman JL, Kizilel S, Skarbek R et al. Immunoisolating pancreatic islets by encapsulation 
with selective withdrawal. Small 2007: 3: 683-690. 
Page 70 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
71 
 
 
 
 
 
 
258. Cruise GM, Hegre OD, Scharp DS, Hubbell JA. A sensitivity study of the key parameters in 
the interfacial photopolymerization of poly(ethylene glycol) diacrylate upon porcine islets 
Biotechnol. Bioeng. 1998: 57: 655-665. 
259. Blasi P, Luca G, Mancuso F et al. Conformal polymer coatings for pancreatic islets 
transplantation. Int. J. Pharm 2013: 440: 141-147. 
260. Teramura Y, Iwata H. Bioartificial pancreas: Microencapsulation and conformal coating of 
islet of Langerhans. Adv. Drug Delivery Rev. 2010: 62: 827-840. 
261. Kizilel S, Scavone A, Liu X et al. Encapsulation of pancreatic islets within nano-thin 
functional polyethylene glycol coatings for enhanced insulin secretion. Tissue Eng. Part A. 2010: 
16: 2217-2228. 
262. Luan NM, Teramura Y, Iwata H. Layer-by-layer co-immobilization of soluble complement 
receptor 1 and heparin on islets. Biomaterials 2011: 32: 6487-6492. 
263. Teramura Y, Oommen OP, Olerud J, Hilborn J, Nilsson B. Microencapsulation of cells, 
including islets, within stable ultra-thin membranes of maleimide-conjugated PEG-lipid with 
multifunctional crosslinkers. Biomaterials. 2013: 34: 2683-2693. 
264. Sorelle JA, Kanak MA, Itoh T, Horton JM, Naziruddin B, Kane RR. Comparison of surface 
modification chemistries in mouse, porcine, and human islets. J Biomed Mater Res Part A. 2015: 
103A: 869-877. 
Page 71 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
72 
 
 
 
 
 
 
265. Kozlovskaya V, Zavgorodnya O, Kharlampieva E. 2012. Encapsulation and surface 
engineering of pancreatic islets: Advances and challenges.  In Biomedicine, C. Lin (Ed.), Ch.1, 
pp. 1-32, InTech, (ISBN 978-953-51-0352-3). 
266. Wilson JT, Cui W, Kozlovskaya V et al. Cell surface engineering with polyelectrolyte 
multilayer thin films. J. Am. Chem. Soc. 2011: 133: 7054-7064. 
267. Wilson JT, Krishnamurthy VR, Cui W, Qu Z, Chaikof EL. Noncovalent cell surface 
engineering with cationic graft copolymers. J. Am. Chem. Soc. 2009: 131: 18228-18229. 
268. Nöth U, Gröhn P, Jork A et al. 19F-MRI in vivo determination of the partial oxygen 
pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and 
different tissues. Magn Reson Med. 1999: 42: 1039-1047. 
269. Toso C, Mathe Z, Morel P et al. Effect of microcapsule composition and short-term 
immunosuppression on intraportal biocompatibility. Cell Transplant. 2005: 14: 159-167. 
270. Mai G, Huy NT, Morel P et al. Treatment of fulminant liver failure by transplantation of 
microencapsulated primary or immortalized xenogeneic hepatocytes. Transplant Proc. 2005: 37: 
527-529. 
271. Mai G, Huy NT, Morel P et al. Treatment of fulminant liver failure by transplantation of 
microencapsulated primary or immortalized xenogeneic hepatocytes. Xenotransplantation. 2005: 
12: 457-464. 
Page 72 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
73 
 
 
 
 
 
 
272. T, Aomatsu Y, Iwata H et al. Indefinite islet protection from autoimmune destruction in 
nonobese diabetic mice by agarose microencapsulation without immunosuppression. 
Transplantation. 2003: 75: 619-625. 
273. Kobayashi T, Arefanian H, Harb G et al. Prolonged survival of microencapsulated neonatal 
porcine islet xenografts in immune-competent mice without antirejection therapy. Cell 
Transplant. 2008: 17: 1243-1256. 
274. Kobayashi T, Harb G, Rayat GR. Prolonged survival of microencapsulated neonatal porcine 
islets in mice treated with a combination of anti-CD154 and anti-LFA-1cmonoclonal antibodies. 
Transplantation. 2005: 80: 821-827. 
275. Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr 
Diab Rep. 2011: 11: 364-374. 
276. Tuch BE, Keogh GW, Williams LJ et al. Safety and viability of microencapsulated human 
islets transplanted into diabetic humans. Diabetes Care. 2009: 32: 1887-1889. 
277. Safley SA, Cui H, Cauffiel S, Tucker-Burden C, Weber CJ. Biocompatibility and immune 
acceptance of adult porcine islets transplanted intraperitoneally in diabetic NOD mice in calcium 
alginate poly-L-lysine microcapsules versus barium alginate microcapsules without poly-L-
lysine. J Diabetes Sci Technol 2008: 2: 760-767. 
278. Kin T, Korbutt GS, Rajotte RV. Survival and metabolic function of syngeneic rat islet grafts 
transplanted in the omental pouch. Am J Transplant. 2003: 3: 281-285. 
Page 73 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
74 
 
 
 
 
 
 
279. Kobayashi T, Aomatsu Y, Iwata H et al. Survival of microencapsulated islets at 400 days 
posttransplantation in the omental pouch of NOD mice. Cell Transplant. 2006: 15: 359-365. 
280. Kobayashi T, Aomatsu Y, Kanehiro H, Hisanaga M, Nakajima Y. Protection of NOD islet 
isograft from autoimmune destruction by agarose microencapsulation. Transplant Proc. 2003: 35: 
484-485. 
281. Fort A, Fort N, Ricordi C, Stabler Cl. Biohybrid devices and encapsulation technologies for 
engineering a bioartificial pancreas. Cell Transplant. 2008: 17: 997-1003. 
282. Veriter S, Mergen J, Goebbels Rm et al. In vivo selection of biocompatible alginates for islet 
encapsulation and subcutaneous transplantation. Tissue Eng Part A. 2010: 16: 1503-1513. 
283. Wang W, Gu Y, Tabata Y et al. Reversal of diabetes in mice by xenotransplantation of a 
bioartificial pancreas in a prevascularized subcutaneous site. Transplantation. 2002: 73: 122-129. 
284. Petrelli A, Carvello M, Vergani A et al. IL-21 is an antitolerogenic cytokine of the late-
phase alloimmune response. Diabetes. 2011: 60: 3223-3234. 
285. Juang JH, Shen CR, Wang JJ et al. Magnetic resonance imaging study of mouse islet 
allotransplantation. Transplant Proc. 2010: 42: 4217-4220. 
286. Cooper DKC, Bottino R, Satyananda V, Wijkstrom M, Trucco M. Toward clinical islet 
xenotransplantation – are revisions to the IXA guidelines warranted? Xenotransplantation 2013: 
20: 68-74. 
Page 74 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
75 
 
 
 
 
 
 
287. Reichart B, Niemann H, Chavakis T et al. Xenotransplantation of porcine islet cells as a 
potential option for the treatment of type 1 diabetes in the future. Horm Metab Res 2015: 47: 31-
35. 
288. Shin JS, Kim JM, Kim JS et al. Long-term control of diabetes in immunosuppressed 
nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant 2015: 
15: 2837-2850. 
289. Zhu H, Yu L, He Y et al. Microencapsulated pig islet xenotransplantation as an alternative 
treatment of diabetes. Tissue Eng. Part B. 2015: 21: 474-489. 
290. Jimenez-Vera E, Davies S, Phillips P et al. Long-term cultured neonatal islet cell clusters 
demonstrate better outcomes for reversal of diabetes: in vivo and molecular profiles. 
Xenotransplantation. 2015: 22: 114-123. 
291. Van Bürck L, Seissler J. The potential of local immunomodulation and tolerance induction 
in porcine islet xenotransplantation. Xenostransplantation 2013: 20: 51. 
292. Nagaraju S, Bottino R, Wijkstrom M et al. Islet xenotransplantation: what is the optimal age 
of the islet-source pig? Xenotransplantation 2015: 22: 7-19. 
293. Bottino R, Wijkstrom M, van der Windt DJ et al. Pig-to-monkey islet xenotransplantation 
using multi-transgenic pigs. Am J Transplant. 2014: 14: 2275-2287. 
Page 75 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
76 
 
 
 
 
 
 
294. Ramackers W, Klose J, Vondran FWR et al. Species-specific regulation of fibrinogen 
synthesis with implications for porcine hepatocyte xenotransplantation. Xenotransplantation 
2014: 21: 444-453. 
295. Ham DS, Song MS, Park HS et al. Successful xenotransplantation with re-aggregated and 
encapsulated neonatal pig liver cells for treatment of mice with acute liver failure. 
Xenotransplantation 2015: 22: 249-259. 
296. No DY, Jeong GS, Lee SH. Immune-protected xenogeneic bioartificial livers with liver-
specific microarchitecture and hydrogel-encapsulated cells. Biomaterials 2014: 35: 8983-8991. 
297. Wright JR Jr, Yang H, Hyrtsenko O et al. A review of piscine islet xenotransplantation using 
wild-type tilapia donors and the production of transgenic tilapia expressing a “humanized” tilapia 
insulin. Xenotransplantation 2014: 21: 485-495. 
298. White DJ. Fish islet xenografts. Xenotransplantation 2014: 21: 124-126. 
299. Safley SA, Cui H, Cauffiel SMD et al. Encapsulated piscine (tilapia) islets for diabetes 
therapy: studies in diabetic NOD and NOD-SCID mice. Xenotransplantation 2014: 21: 127-139. 
300. Schneider S, Feilen PJ, Brunnenmeier F et al. Long-term graft function of adult rat and 
human islets encapsulated in novel alginate-based microcapsules after transplantation in 
immunocompetent diabetic mice. Diabetes. 2005: 54: 687-693. 
301. Omer A, Duvivier-Kali V, Fernandes J et al. Long-term normoglycemia in rats receiving 
transplants with encapsulated islets. Transplantation. 2005: 79: 52-58. 
Page 76 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
77 
 
 
 
 
 
 
302. Gomez N, Balladur P, Calmus Y et al. Evidence for survival and metabolic activity of 
encapsulated xenogeneic hepatocytes transplanted without immunosuppression in Gunn rats. 
Transplantation. 1997: 63: 1718-1723. 
303. Kin T, Korbutt GS, Rajotte RV. Normalization of diabetes in spontaneously diabetic 
cynomologus monkeys by xenografts of microencapsulated porcine islets without 
immunosuppression. J Clin Invest. 1996: 98: 1417-1422. 
304. Basta G, Montanucci P, Luca G et al. Long-term metabolic and immunological follow-up of 
nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet 
allografts: four cases. Diabetes Care. 2011: 34: 2406-2409. 
305. Matsumoto S, Tan P, Baker J, Durbin K, Tomiya M, Azuma K, Doi M, Eliott RB. Clinical 
porcine islet xenotransplantation under comprehensive regulation. Transplant Proc. 2014: 46: 
1992-1995. 
306. Ludwig B, Ludwig S. Transplantable bioartificial pancreas devices: current status and future 
prospects. Langenbecks Arch Surg. 2015: 400: 531-540. 
307. De Vos P, Van Straaten JF, Nieuwenhuizen AG et al. Why do microencapsulated islet grafts 
fail in the absence of fibrotic overgrowth? Diabetes. 1999: 48: 1381-1388. 
308. De Vos P, Vegter D, Strubbe JH, De Haan BJ, Van Schilfgaarde R. Impaired glucose 
tolerance in recipients of an intraperitoneally implanted microencapsulated islet allograft is 
Page 77 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
78 
 
 
 
 
 
 
caused by the slow diffusion of insulin through the peritoneal membrane. Transplant Proc. 1997: 
29: 756-757. 
309. Cooper DKC. The case for xenotransplantation. Clin Transplant. 2015: 29: 288-293. 
310. Ellis CE, Korbutt GS. Justifying clinical trials for porcine islet xenotransplantation. 
Xenotransplantation 2015: 22: 336-344. 
311. Agudelo CA, Teramura Y, Iwata H. Cryopreserved agarose-encapsulated islets as 
bioartificial pancreas: a feasibility study. Transplantation. 2009: 87: 29-34. 
312. Schneider S, Klein HH. Long-term graft function of cryostored alginate encapsulated rat 
islets. Eur J Med Res. 2011: 16: 396-400. 
  
Page 78 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
79 
 
 
 
 
 
 
Table 1. Selected alg-based physical hydrogels applied for cell microencapsulation 
Divalent 
ions 
Cell type Target Reference 
Ca
2+ 
BMSC
1 
Hepatocytes 
Pig islets 
ADSC
2 
CSP
3 
Treatment of stress urinary incontinence 
Development of bio-artificial liver 
Impact of implantation sites on the biocompatibility 
Study of angiogenic and osteogenic potential of ADSC 
Therapeutic approach for cartilage regeneration 
[50] 
[51] 
[52] 
[53, 54] 
[55] 
Ba
2+ 
Rat islets 
Neuroblastoma 
WJMSC
4
 
Study of islets function in vitro and in vivo 
Cryopreservation of neurospheres by encapsulation 
Optimized microencapsulation of MSC by vibrational nozzle 
[56] 
[57] 
[58] 
Ba
2+
/Ca
2+ Human islets 
ARPE-19
5 
Viability and function after transplantation into diabetic mice. 
In vitro study of encapsulated human retinal pigment epithelial cells 
[59, 60] 
[61] 
1
Bone marrow mesenchymal stem cells; 
2
Adipose-derived stem cells; 
3
Human mesenchymal progenitor cells 
from the subchondral bone marrow; 
4
Wharton's jelly mesenchymal stem cells; 
5
Human retinal pigment epithelial 
cells 
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Table 2. Examples of chemical hydrogels applied for cell immobilization 
Material Preparation Cell Reference 
Alginate 
Click reaction with tetrazine-norbornene modified hydrogel 
(no ionic cross-linkings) 
EGFP-expressing 3T3 
fibroblast 
[140] 
PEG 
Thiol-ene reaction of PEG diacrylate with thiolated gelatin Fibroblasts; keratinocytes [141, 142] 
Maleimide, acrylate and vinyl sulfone-modified PEG cross-
linked with peptides 
C2C12 myoblast [143] 
Photo-polymerization of fibrinogen-g-PEGacryloyl and PEG 
diacrylate 
BMSC 
[144] 
Photo-polymerization of PEG diacrylate Huh-7.5 [145] 
Chitosan 
Photo-polymerization of chitosan grafted with lactic acid and 
methacrylate Chondrocytes 
 
[146] 
Chemically cross-linked chitosan hydrogel loaded with gelatin [147] 
N-succinyl-chitosan gelation with aldehyde hyaluronic acid [148] 
Dextran 
Photo-polymerization of dextran with benzophenone Osteoblast-endothelial cell [149] 
Gelation of methacrylate and lysine functionalized dextran Smooth muscle cells [150] 
Photopolymerization of dextran-acrylate Embryonic stem cells [151] 
HA 
HA cross-linked via disulfide bond formation reaction Fibroblasts, stem cells [152] 
Methacrylated HA cross-linked by UV exposure MSC [153] 
Peroxidase catalyzed oxidation of tyramine-substituted HA Chondrocytes [154] 
Conjugate addition of thiol-modified HA onto PEG diacrylate Adipocyte-stem cells [155] 
PVA 
UV photopolymerization 
L929 fibroblast 
[156] 
Click hydrogels formed by hydrazone bonds [157] 
PEG: Poly(ethylene glycol); HA: Hyaluronic acid; PVA: Poly(vinyl alcohol); MSC: Mesenchymal stem cell 
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Table 3. Xenotransplantation of encapsulated cells in animal models 
Transplanted 
model 
Cell type Transplantation site 
Materials for 
encapsulation 
Reference 
Mice 
Neonatal porcine islets Peritoneal cavity Ca-alg and Ba-alg 
[273] 
[274] 
Rat islets 
Subcutaneous tissue 
 
Intraperitoneal space 
Peritoneal cavity 
Agarose / poly (styrene 
sulfonic acid) 
Alg-PLL-PEG 
Agarose 
[283] 
 
[80] 
[187] 
Human islets 
Omental pouch 
Peritoneal cavity 
Agarose 
Ba-alg 
[279] 
[300] 
Neonatal pig hepatocytes Abdominal cavity Ba-alg [295] 
Rat hepatocytes 
Human hepatocytes 
Peritoneal cavity 
 
Alg-PLL-alg 
 
[270, 271] 
 
Fish islets Abdominal cavity Ba-alg [299] 
Rat 
Pig islets 
Subcutaneous tissue 
Abdominal cavity 
Ca-alg 
Ba-alg 
[282] 
[301] 
Guinea pig hepatocytes 
Peritoneal cavity acrylonitrile-sodium 
methallyl-sulfonate 
copolymer 
[302] 
Non human 
primates 
Pig islets 
Intraportal injection No material 
 
[288] 
[293] 
Intraperitoneal space Ca-alg-PLL [303] 
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Fig. 1. Schematic representation of cell microencapsulation. 
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Fig. 2. Principles to form physical hydrogels by ionic bonding. 
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Fig. 3. Na-alg consists of α-L-guluronic and β-D-manuronic acid residues. 
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Fig. 4. The properties of alg-based hydrogels depend on the nature of the applied Na-alg, (solid 
line) confirmed influence, (dotted line) controversially discussed. 
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Fig. 5. Chemical structure of poly(L-lysine) hydrochloride and poly(L-ornithine) hydrochloride. 
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Fig. 6. The chemical structure of chitosan. 
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Fig. 7. The chemical structures of sodium cellulose sulfate (CS) and poly(methylene-co-
guanidine) hydrochloride (PMCG). 
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Fig. 8. Formation of droplets by: coaxial air-flow (1), electrostatic potential (2), rotating disk (jet 
cutter) (3), and vibrating nozzle (4). Cells are finally entrapped in hydrogel microspheres after 
falling down in the gelation bath. 
  
Page 89 of 102
Xenotransplantation
Xenotransplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
90 
 
 
 
 
 
 
 
Fig. 9. Comparison of conformal coating and cell microencapsulation. 
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Figure 1. Schematic representation of cell microencapsulation  
95x73mm (72 x 72 DPI)  
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Figure 2. Principles to form physical hydrogels by ionic bonding  
214x85mm (72 x 72 DPI)  
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Figure 3. Na-alg consists of α-L-guluronic and β-D-manuronic acid residues  
209x67mm (72 x 72 DPI)  
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Figure 4. The properties of alg-based hydrogels depend on the nature of the applied Na-alg, (solid line) 
confirmed influence, (dotted line) controversially discussed  
168x74mm (72 x 72 DPI)  
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Figure 5. Chemical structure of poly(L-lysine) hydrochloride and poly(L-ornithine) hydrochloride  
40x65mm (300 x 300 DPI)  
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Figure 6. The chemical structure of chitosan  
124x55mm (72 x 72 DPI)  
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Figure 7. The chemical structures of sodium cellulose sulfate (CS) and poly(methylene-co-guanidine) 
hydrochloride (PMCG)  
81x68mm (300 x 300 DPI)  
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Figure 8. Formation of droplets by: coaxial air-flow (1), electrostatic potential (2), rotating disk (jet cutter) 
(3), and vibrating nozzle (4). Cells are finally entrapped in hydrogel microspheres after falling down in the 
gelation bath  
213x96mm (72 x 72 DPI)  
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Figure 9. Comparison of conformal coating and cell microencapsulation  
154x50mm (72 x 72 DPI)  
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Table 1. Selected alg-based physical hydrogels applied for cell microencapsulation 
Divalent 
ions 
Cell type Target Reference 
Ca
2+ 
BMSC
1 
Hepatocytes 
Pig islets 
ADSC
2 
CSP
3 
Treatment of stress urinary incontinence 
Development of bio-artificial liver 
Impact of implantation sites on the biocompatibility 
Study of angiogenic and osteogenic potential of ADSC 
Therapeutic approach for cartilage regeneration 
[50] 
[51] 
[52] 
[53, 54] 
[55] 
Ba
2+ 
Rat islets 
Neuroblastoma 
WJMSC
4
 
Study of islets function in vitro and in vivo 
Cryopreservation of neurospheres by encapsulation 
Optimized microencapsulation of MSC by vibrational nozzle 
[56] 
[57] 
[58] 
Ba
2+
/Ca
2+ Human islets 
ARPE-19
5 
Viability and function after transplantation into diabetic mice. 
In vitro study of encapsulated human retinal pigment epithelial cells 
[59, 60] 
[61] 
1
Bone marrow mesenchymal stem cells; 
2
Adipose-derived stem cells; 
3
Human mesenchymal progenitor cells 
from the subchondral bone marrow; 
4
Wharton's jelly mesenchymal stem cells; 
5
Human retinal pigment epithelial 
cells 
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Table 2. Examples of chemical hydrogels applied for cell immobilization 
Material Preparation Cell Reference 
Alginate Click reaction with tetrazine-norbornene modified hydrogel (no ionic cross-linkings) 
EGFP-expressing 3T3 
fibroblast [140] 
PEG 
Thiol-ene reaction of PEG diacrylate with thiolated gelatin Fibroblasts; keratinocytes [141, 142] 
Maleimide, acrylate and vinyl sulfone-modified PEG cross-
linked with peptides C2C12 myoblast [143] 
Photo-polymerization of fibrinogen-g-PEGacryloyl and PEG 
diacrylate 
BMSC [144] 
Photo-polymerization of PEG diacrylate Huh-7.5 [145] 
Chitosan 
Photo-polymerization of chitosan grafted with lactic acid and 
methacrylate Chondrocytes 
 
[146] 
Chemically cross-linked chitosan hydrogel loaded with gelatin [147] 
N-succinyl-chitosan gelation with aldehyde hyaluronic acid [148] 
Dextran 
Photo-polymerization of dextran with benzophenone Osteoblast-endothelial cell [149] 
Gelation of methacrylate and lysine functionalized dextran Smooth muscle cells [150] 
Photopolymerization of dextran-acrylate Embryonic stem cells [151] 
HA 
HA cross-linked via disulfide bond formation reaction Fibroblasts, stem cells [152] 
Methacrylated HA cross-linked by UV exposure MSC [153] 
Peroxidase catalyzed oxidation of tyramine-substituted HA Chondrocytes [154] 
Conjugate addition of thiol-modified HA onto PEG diacrylate Adipocyte-stem cells [155] 
PVA UV photopolymerization L929 fibroblast [156] Click hydrogels formed by hydrazone bonds [157] 
PEG: Poly(ethylene glycol); HA: Hyaluronic acid; PVA: Poly(vinyl alcohol); MSC: Mesenchymal stem cell 
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Table 3. Xenotransplantation of encapsulated cells in animal models 
Transplanted 
model 
Cell type Transplantation site 
Materials for 
encapsulation 
Reference 
Mice 
Neonatal porcine islets Peritoneal cavity Ca-alg and Ba-alg 
[273] 
[274] 
Rat islets 
Subcutaneous tissue 
 
Intraperitoneal space 
Peritoneal cavity 
Agarose / poly (styrene 
sulfonic acid) 
Alg-PLL-PEG 
Agarose 
[283] 
 
[80] 
[187] 
Human islets 
Omental pouch 
Peritoneal cavity 
Agarose 
Ba-alg 
[279] 
[300] 
Neonatal pig hepatocytes Abdominal cavity Ba-alg [295] 
Rat hepatocytes 
Human hepatocytes 
Peritoneal cavity 
 
Alg-PLL-alg 
 
[270, 271] 
 
Fish islets Abdominal cavity Ba-alg [299] 
Rat 
Pig islets 
Subcutaneous tissue 
Abdominal cavity 
Ca-alg 
Ba-alg 
[282] 
[301] 
Guinea pig hepatocytes 
Peritoneal cavity acrylonitrile-sodium 
methallyl-sulfonate 
copolymer 
[302] 
Non human 
primates 
Pig islets 
Intraportal injection No material 
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Intraperitoneal space Ca-alg-PLL [303] 
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